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GAT107 IMPROVES SURVIVAL BY ATTENUATING HYPEROXIA-COMPROMISED 
HOST DEFENSE IN BACTERIAL CLEARANCE IN THE LUNGS VIA ALLEVIATING THE 
REDOX IMBALANCE IN MACROPHAGES 
 
Alex G. Gauthier 
 
Prolonged exposure to hyperoxia can compromise macrophage bacterial clearance 
functions, contributing to the increased susceptibility to pulmonary infections 
observed in hospital and ventilator-associated pneumonia (HAP/VAP). Previously 
studies in our lab demonstrate that activation of the α7 nicotinic acetylcholine 
receptor (α7nAChR) has protective effects against proinflammatory lung injury in 
animals subjected to prolonged hyperoxic exposure and bacterial infections. In this 
study, we demonstrated that administration of GAT107, an α7nAChR agonistic 
positive allosteric modulator (ago-PAM), improved survival by attenuating 
hyperoxia-compromised bacterial clearing functions of mice with Pseudomonas 
aeruginosa (PA) lung infection. GAT107  decreased the bacterial burden in mice lungs 
by attenuating the hyperoxia-compromised phagocytic functions of both cultured 
macrophages, RAW 264.7 cells, and those isolated from mice. In hyperoxia-exposed 
RAW macrophages, GAT107 treatment attenuated oxidation of F-actin, a critical 
cytoskeletal component involved in phagocytosis. In hyperoxia-compromised mice 
with PA lung infection, GAT107 ameliorated hyperoxia-induced oxidative stress 
levels and increased the antioxidant oxidant potential in lung tissues and also in 
cultured macrophages. GAT107 induced the activation of the master antioxidant 
transcription factor, Nrf2, and significantly increased the levels of its down-stream 
antioxidant heme oxygenase-1 (HO-1) protein in macrophages. In macrophages, 
 
hyperoxia induced mitochondrial membrane perturbation and also elevated 
mitochondrial superoxide (mitoSOX) levels, which was attenuated with GAT107 
treatment. GAT107 decreased mitoSOX via attenuating hyperoxia-compromised 
manganese superoxide dismutase (MnSOD) activity and had no effect on its total 
protein levels. MnSOD activity was found to be strongly correlated with the extent of 
cysteine glutathionylation, which was attenuated in GAT107-treated macrophages. 
Thus, these data suggest that GAT107 provides protective effects against PA 
infection-induced inflammatory lung injury via attenuating hyperoxia-impaired 
macrophage function via restoring redox balance. GAT107-elicited efficacy in 
macrophage functions under hyperoxic conditions is through restoring the redox 
imbalance mediated partly by mitochondrial stress and MnSOD functions. Thus, 
GAT107 may be a potential therapeutic agent acting to improve host defense 
functions in the subjects exposed to prolonged periods of hyperoxia, such as VAP, 
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1.1. Hyperoxia-Induced Compromise of Host Defense Functions and 
Ventilator-Associated Pneumonia  
 Oxygen therapy, using concentrations of supplemental oxygen up to 100% 
(hyperoxia), is a routine treatment for intensive care units (ICU) patients, surgical 
patients, pre-term neonates, patients with acute lung injury (ALI) / acute respiratory 
distress syndrome (ARDS), patients requiring home oxygen therapy care such as 
those with chronic obstructive pulmonary disorder (COPD), and in patients receiving 
supportive care for airway-associated infections, such as the novel COVID-19 
coronavirus (Branson, 2018; Magnet et al., 2017; Renda et al., 2018; Walsh and 
Smallwood, 2017; Wang et al., 2020). Although oxygen therapy is a lifesaving 
intervention, prolonged exposure to hyperoxia to patients can compromise lung host 
defense and cause inflammatory acute lung injury (ALI) (Kallet and Matthay, 2013; 
Pham et al., 2017). Consequently, patients with compromised host defense and 
exposed to hyperoxia, experience a higher susceptibility to pulmonary bacterial 
infections that cause ventilator-associated pneumonia (VAP) and hospital-acquired 
pneumonia (HAP) (Bassi et al., 2014; Oliveira et al., 2014). Approximately one-third 
of all MV ICU patients develop VAP, which has a 4.6% mortality rate (Rello, 2005; 
Rello et al., 2002; Spalding et al., 2017). Oftentimes, Medicaid denies insurance claim 
reimbursement for these patients since the disease was acquired under hospital care, 
placing increased financial burden on both the patient and the hospital (Rello et al., 
2002; Spalding et al., 2017). VAP patients have to pay large amounts of out-of-pockets 
expenses to cover the increased medical costs for care, which ranges from about 
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$20,000 to $100,000 and averages approximately $40,000 per case of VAP (Kollef et 
al., 2012; Rello et al., 2002; Zimlichman et al., 2013).  
The antimicrobial functions of the innate immune defense system of the lung is 
complex and depends on the type of pathogen or pathogen/damage associated 
molecular pattern (P/DAMP) and their location within the airways (Martin and 
Frevert, 2005). Larger particle pathogens that enter the nasopharynx or conducting 
airways can become trapped in mucociliary surfaces where they can be expelled 
through a mucociliary clearance mechanism (Martin and Frevert, 2005). Smaller 
substances of 1µm diameter or less can be deposited into the deeper conducting 
airways of the bronchioles and alveoli. In the alveoli, the leukocyte population is 
composed of 95% macrophages (60-70% alveolar and 30-40% are interstitial 
macrophages), 1-4% lymphocytes, and 1% neutrophils (Martin and Frevert, 2005; 
Tan and Krasnow, 2016). Alveolar macrophages are a first line of defense against 
invading pathogens that enter the distal airways (Allard et al., 2018; Byrne et al., 
2015; Craven et al., 1986). The alveolar environment is enriched with high levels of 
opsonizing immunoglobulins (e.g. IgG and IgA) and lipid binding protein, which 
augment the host defense response of alveolar macrophages to phagocytose invading 
pathogens (Martin and Frevert, 2005).  
It is estimated that average adult intake of total air is approximately 10,000 L per day, 
which contains 2,100 L of oxygen (Hartl et al., 2018). In patients receiving oxygen 
therapy, oxygen concentrations often reach 100%, increasing the amount of inhaled 
oxygen to 10,000 L. Unlike other organs that rely on oxygenation via perfusion by 
circulating blood, the alveolar macrophages are in direct contact with these hyperoxic 
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levels of oxygen. Alveolar macrophages are derived from yolk-sac fetal monocytes, 
are self-renewing, and can be replenished by interstitial macrophage proliferation 
and differentiation (Tan and Krasnow, 2016). In response to the exposure to 
hyperoxia, the amounts of alveolar macrophage do not change due to the activation 
of cell survival pathways (Baleeiro et al., 2003; Monick et al., 2008; Petrache et al., 
1999). However, in mice and ex vivo alveolar macrophage cultures, prolonged 
exposure to hyperoxia impairs the phagocytosis of bacteria known to produce VAP, 
such as Staphylococcus aureus and Pseudomonas aeruginosa, and certain bacteria 
from the Enterobacteriaceae family (Baleeiro et al., 2003; Barbier et al., 2013; Bassi 
et al., 2014; Chastre and Fagon, 2002).  
Pseudomonas aeruginosa (PA)-induced pneumonia has the highest associated-death 
rates (87%) when compared to all other bacterial pneumonias (55%) (Chastre and 
Fagon, 2002; Cotoia et al., 2020). In VAP patients, PA also has the highest associated-
death rates (65%) when compared to all other bacterial species (31%) (Chastre and 
Fagon, 2002; Cotoia et al., 2020). PA is a multi-drug resistant organism, which is 
normally innocuous in the environment, but can become highly opportunistic in 
immunocompromised patients (Bassetti et al., 2018). In ventilated patients receiving 
oxygen therapy, PA enters the lung usually by contact with contaminated surfaces on 
endotracheal tubes, drainage cuffs, or by direct contact of healthcare workers (Cotoia 
et al., 2020). Upon colonization of PA in the lung, the bacteria utilize a variety of 
virulence factors that cause the breakdown of lipids, elastic fibers, and proteins, 
activate quorum sensing, and elicit an inflammatory response (Hauser, 2011). As a 
consequence, PA pneumonia can disrupt or destroy the alveolar-capillary barrier, 
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resulting in pulmonary edema, hypoxemia, and respiratory failure (Chastre and 
Fagon, 2002; Cotoia et al., 2020; Hauser, 2011).  
Currently, VAP patients with PA pneumonia are treated with cocktails of antibiotics 
including aminoglycosides, cephalosporin, carbapenem, and other broad-spectrum 
antibiotics (Bassetti et al., 2018; Cotoia et al., 2020). However, treatment with these 
antibiotic cocktails for PA pneumonia in VAP has yielded unconvincing clinical results 
of the efficacy of this therapeutic strategy (Cotoia et al., 2020). Thus, other therapies 
that can target more efficient clearance of these pathogenic organisms is critically 
needed. Since alveolar macrophages are a first line of defense in the airways against 
invading pathogens like PA, impairment of macrophage functions cause the increased 
the susceptibility to bacterial infections in animals and humans exposed to hyperoxia 
(Baleeiro et al., 2003; Patel et al., 2013; Reddy et al., 2009; Sitapara et al., 2014). 
Therefore, alveolar macrophages are a potential therapeutic target to improve 
outcomes for individuals that are immunocompromised by hyperoxic oxygen 
therapy. 
1.2. Impact of Hyperoxia on Macrophage Function 
The prolonged exposure of macrophages to hyperoxia induces the elevation of 
intracellular reactive oxygen species (ROS) (Freeman et al., 1982). ROS produce a 
phenomenon known as oxidative stress, a pathophysiological condition characterized 
by the relative higher amount of oxidants to reductants and their correlation with 
disease pathogenesis (Burton and Jauniaux, 2011). Free radicals derived from oxygen 
and other ROS can be controlled through the containment of antioxidant defense 
systems (Aerts et al., 1995; Birben et al., 2012; Cho et al., 2002; Gore et al., 2010). The 
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complex network of antioxidant molecules and enzymes in the cell are critical for 
mitigating oxidative stress and maintain cellular homeostasis (Birben et al., 2012). 
However, prolonged exposure to hyperoxia results in an overwhelming and 
continuous production of ROS, which can surmount the endogenous antioxidant 
defense system and induce mitochondrial damage (Freeman et al., 1982; O’Donovan 
and Fernandes, 2000; Pagano and Barazzone-Argiroffo, 2003). Mitochondrial damage 
by hyperoxic exposure is partly due to the generation of ROS, such as superoxide and 
hydroxyl radicals (Goscin and Fridovich, 1973; Guo et al., 2013; Indo et al., 2015; 
Majima et al., 1998; Morrow et al., 2007). Superoxide is generated by the one electron 
reduction of molecular oxygen and has a half-life of approximately 1-4 µs (Gielis et al., 
2017). Superoxide is commonly generated as a reaction byproduct from cytochromes 
and enzymes containing iron-cores, such as the complexes of the electron transport 
chain (ETC) (Li et al., 2013). Upon the exposure to hyperoxia, intramitochondrial 
levels of oxygen increase (Düssmann et al., 2017), which may augment the basal 
mitochondrial superoxide byproduct formation. Importantly, hyperoxia exposure has 
been shown to decrease the activities of complex I, II, and IV of the ETC, which results 
in increased amounts of electron leakage, and the subsequent reduction of molecular 
oxygen to superoxide anion (Resseguie et al., 2015). Superoxide can then be 
converted to hydrogen peroxide in the mitochondria by manganese superoxide 
dismutase (MnSOD or SOD2) and by copper-zinc SOD (CuZnSOD or SOD1) in the 
cytosol (Wang et al., 2018). Hydrogen peroxide can then be either detoxified into 
water by catalase or permeate out of the mitochondria and contribute to cytosolic 
ROS and cause oxidative stress (Birben et al., 2012; Guo et al., 2013). Excessive 
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mitochondrial superoxide accumulation can cause oxidative damage to ETC enzymes 
and affects the levels and localization of electron carriers (e.g. NADH, FADH2, 
cytochrome C) that are involved in oxidative phosphorylation, resulting in impaired 
energy production, changes in the mitochondrial membrane potential, and the 
additional production of ROS (Bhatti et al., 2017; Guo et al., 2013; Zorova et al., 2018). 
As a consequence, impaired energy production and excessive ROS has profound 
impacts on the phagocytic function of macrophages (Okpala et al., 2015; O’Reilly et 
al., 2003). Macrophage phagocytosis requires readily available pools of ATP 
(Borregaard and Herlin, 1982), which is depleted due to the lack of functional 
mitochondria under hyperoxic conditions (Monick et al., 2008). 
In response to invading pulmonary pathogens, macrophages attempt to eradicate 
these microbes through the activation of bactericidal enzymes like NADPH oxidase 
(NOX2) (Griffith et al., 2009). NOX2 enzymes utilize oxygen as a substrate to generate 
superoxide anion in the cytosol and in the phagolysosomes of phagocytosed 
pathogens (Griffith et al., 2009; Parinandi et al., 2003). In pulmonary epithelial and 
endothelial cells, exposure to hyperoxia results in the increase of cytosolic superoxide 
levels, which was found to be dependent on NOX2 and NOX4 activation (Parinandi et 
al., 2003; Zhang et al., 2003). In hyperoxia-exposed NOX2 null mice, NOX4 activation 
contributes to alveolar capillary barrier dysfunction, pulmonary edema, and 
inflammatory lung injury (Griffith et al., 2009; Pendyala et al., 2009). 
Thus, the combination of mitochondrial generated ROS that permeates into the 
cytosol and also ROS generated in the cytosol contribute to total increase in the 
hyperoxia-induced elevated cytosolic ROS levels in macrophages. As a consequence, 
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high cytosolic ROS levels can cause the oxidation of proteins and lipids resulting in 
the post-translational modification (PTM) of F-actin fibers (Morrow et al., 2007; 
O’Reilly et al., 2003). F-actin is a critical cytoskeletal component that is used by 
macrophages to migrate to and form phagosomes around opsonized pathogens like 
PA (Hartwig and Yin, 1988). As a result, hyperoxia-induced F-actin oxidation 
contributes to the formation of stress fiber filaments, the dysregulation of actin 
polymerization, and impairs the migratory and phagocytosis functions of 
macrophages (Morrow et al., 2007; O’Reilly et al., 2003). The impaired phagocytic 
functions of hyperoxia-induced oxidative stress in macrophages can be attenuated by 
treatment with activators of antioxidant defense pathways like sulforaphane or with 
supplemental antioxidants such as ascorbic acid, n-acetyl cysteine, and exogenous 
superoxide dismutase (SOD) (Morrow et al., 2007; Patel et al., 2020). Importantly, 
antioxidant treatment protects against oxidation of F-actin filaments and restores the 
antibacterial and phagocytic functions of macrophages (Arita et al., 2007; Morrow et 
al., 2007; O’Reilly et al., 2003). Thus, the prolonged exposure to hyperoxia has 
profound deleterious effects on macrophage functions to migrate, phagocytose, and 
kill invading pathogens, which can be protected against by treatment with 
supplemental and activators of antioxidant pathways. 
1.3. The Vagus Nerve Mediated Cholinergic Anti-Inflammatory Pathway 
Alveolar macrophages perform their host defense functions, which are mediated in 
part by both autocrine and paracrine-like signaling of cytokines and chemokines. 
Indeed, the balance between pro- and anti-inflammatory cytokine and chemokine 
production has been previously identified as a neuromodulator mechanism known as 
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the cholinergic anti-inflammatory pathway (Borovikova et al., 2000). The cholinergic 
anti-inflammatory pathway is mediated by the vagus nerve, which is the 10th cranial 
nerve (Tracey, 2002). In response to damage, pathogens, or inflammatory signals, the 
afferent vagus nerve conduct signals to the central nervous system where they are 
integrated and relayed to effector organs via the efferent vagus nerve. Acetylcholine 
is released from the efferent vagus nerve innervating pulmonary neuroendocrine 
cells and can bind to macrophage α7 nicotinic acetylcholine receptors (α7nAChRs) 
and downregulate hyper-inflammatory responses, such as those during VAP (Pavlov 
et al., 2003). In addition, cholinergic anti-inflammatory pathway-mediated signaling 
has been identified as a missing link that plays a role in controlling autophagy and 
regulating cellular metabolic homeostasis (Chang et al., 2019; Lu et al., 2014).  
1.4. α7nAChR as a Pharmacological Target for Attenuating Hyperoxia-
Compromised Macrophage Functions  
Previously, we and others have shown that the hyperoxia-compromised innate 
immune functions of alveolar macrophages are significantly attenuated by 
pharmacological activators of the α7 nicotinic acetylcholine receptors (α7nAChRs) 
(Ulloa, 2005; Wang et al., 2004). The α7nAChR is a homomeric pentamer and a  
ligand-gated ion channel found on both neuronal and non-neuronal cells (Báez-Pagán 
et al., 2015; Bagdas et al., 2016; Papke et al., 2018). Upon stimulation with 
endogenous acetylcholine, choline or other agonists, there is a rapid influx of calcium 
ions into neurons that activate certain calcium-dependent pathways (Báez-Pagán et 
al., 2015; Hoover, 2017). Evidence suggests that the activation of non-neuronal cells, 
such as macrophages, produces an influx of calcium ions but does not significantly 
change whole cell currents (Skok, 2009; Villiger et al., 2002). A number of studies 
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have shown that the activation of peripheral α7nAChR produces anti-inflammatory 
effects (de Jonge et al., 2005; Papke et al., 2018; Wang et al., 2003). It has been 
postulated that the anti-inflammatory effect produced by the activation of α7nAChR 
on peripheral immune cells such as macrophages may be due to: 1) inhibition of the 
phosphorylation of the transcription factor STAT3, which subsequently decreases the 
activation of certain genes that produce inflammatory cytokines (Báez-Pagán et al., 
2015); 2) activation of the PI3K/Akt/Nrf2 antioxidant pathway and induction of 
heme oxygenase-1 (HO-1) and 3) the inhibition of NF-kB p65 subunit 
phosphorylation and subsequent nuclear-translocation through STAT3-NF-kB 
convergence (Báez-Pagán et al., 2015; Hoover, 2017). 
Previously, our lab has shown that administration of GTS-21, a partial agonist of the 
α7nAChR, significantly increased bacterial clearance and decreased lung injury in 
hyperoxia-exposed mice with PA pneumonia (Sitapara et al., 2014). Importantly, GTS-
21 activates the cholinergic anti-inflammatory pathway, which in turn has been 
shown to attenuate the phagocytic function of macrophages compromised by the 
prolonged exposure to hyperoxia (Sitapara et al., 2014). However, other clinically 
relevant endpoints, such as mortality rates, were not significantly affected by GTS-21 
administration (unpublished results). Moreover, treatment with α7nAChR agonists 
like acetylcholine, attenuates mitochondrial perturbation in LPS-primed mouse 
primary macrophages (Lu et al., 2014). Yet, it remains unclear if macrophage innate 
immune functions can be improved by attenuating mitochondrial dysfunction. 
Consequently, we wanted to ascertain the efficacy of a next generation α7nAChR 
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activator in animals and in an in vitro model, where macrophage functions are 
compromised by hyperoxia exposure.  
1.5. GAT107 and Agonistic Positive-Allosteric Modulators  
In this study, we determined the efficacy of the (+) - enantiomer of racemic 4-(4-
bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-sulfonamide, 
GAT107, to attenuate hyperoxia-induced impairment of host innate immune 
functions and its underlying mechanisms. GAT107 is positive allosteric modulator 
(PAM) and direct allosteric activator (DAA) that 1) augments or potentiates the 
response to orthosteric site ligands and 2) activates the α7nAChR ion channel (in the 
absence of an orthosteric agonist) by binding to an allosteric site distinct from that of 
the PAM site (Bagdas et al., 2016; Horenstein et al., 2016; Papke et al., 2018, 2014; 
Thakur et al., 2013). In vitro, the α7nAChR can be rapidly desensitized by 
acetylcholine (ACh). Interestingly, the coadministration of GAT107 with ACh 
produces a significant decrease in the ACh-induced desensitization (Horenstein et al., 
2016, 2016; Papke et al., 2014). It is likely that GAT107 facilitates the conversion of 
desensitized states to conducting states which surmounts receptor desensitization 








1.6. Hypothesis  
GAT107 improves the survival of hyperoxia-compromised mice challenged with 
Pseudomonas aeruginosa (PA) lung infection via enhancing host defense functions of 
macrophages. 
Aim 1: To determine if GAT107 improves survival in mice exposed to hyperoxia and 
challenged with PA lung infection. 
Aim 2: To determine if GAT107 attenuates hyperoxia-compromised host defense of 
PA bacterial clearance in the lungs of mice. 
Aim 3: To determine if GAT107 attenuates hyperoxia-induced phagocytic dysfunction 
modulating redox imbalance in macrophages.  
Aim 4: To determine if GAT107 can ameliorate hyperoxia-induced mitochondrial 




2. MATERIALS AND METHODS 
2.1. Cell Culture and Special Reagents 
Murine macrophage–like RAW 264.7 cells (TIB-71; American Type Culture Collection 
(ATCC), Manassas, VA) were cultured in Dulbecco's Modified Eagle Medium (DMEM) 
and supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA). Cells were 
maintained at 37˚C in normoxia (5% CO2/21% O2) for 24 h, allowed to grow to 70–
80% confluency and subcultured every 2 days. Bone marrow was harvested from 6-
8-week-old male C57BL/6 mice (Jackson laboratories), isolated, and cultured to allow 
for differentiation into bone marrow-derived macrophages (BMDM), as previously 
described (Weischenfeldt and Porse, 2008). Hyperoxic exposure was performed in 
sealed, humidified chambers (Billups-Rothenberg Inc., Del Mar, CA) flushed with 95% 
O2/5% CO2 at 37˚C. An oxygen analyzer (MSA Medical Products, Pittsburgh, PA) was 
used to monitor the O2 levels.  
2.2. Animal Studies 
Male C57BL/6 mice (6 to 10 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA) 
were used in this investigation based on a protocol (protocol #1953) approved by the 
Institutional Animal Care and Use Committees of St. John’s University. The mice were 
housed in a specific pathogen-free environment, maintained at 22°C in ≈50% relative 
humidity and with a 12 h light/dark cycle. All mice had ad libitum access to standard 
rodent food and water. Mice were randomized to receive either 3.3 mg/kg of ((+) - 
(4-(4-bromophenyl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline-8-
sulfonamide, GAT107, donated by Dr. Ganesh S. Thakur, Northeastern University, 
Boston, MA, or saline, administered by intraperitoneal injection at 24, 36, and 48 h 
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after the onset of hyperoxic exposure. After 48 h of exposure, the mice were 
inoculated with 0.1 × 108 colony-forming units (CFUs) of Pseudomonas aeruginosa 
(PA) by making a 1- to 2-cm incision on the neck to expose the trachea after 
anesthetization with sodium pentobarbital (75 mg/kg). PA was used as the selected 
pathogen as it is associated with 21% of all VAP cases (Richards et al., 1999). Twenty 
four hours after bacterial inoculation, mice were euthanized via exsanguination and 
bronchoalveolar lavage (BAL) and lung tissues were immediately collected as 
described previously (Patel et al., 2013). For the collection of BAL, the lungs were 
lavaged with PBS, and afterwards, the lungs were excised and immediately placed 
into 1 mL cold PBS containing a protease and phosphatase inhibitors cocktail (Pierce 
Thermo Scientific) followed by homogenization by a Dounce tissue homogenizer. 
For animal survival studies, mice were subjected for 72 h of hyperoxia exposure and 
inoculated similarly as stated above. Mice were then monitored every hour over the 
course of 24 h for survival. 
2.3. Exposure to Hyperoxia 
Male C57BL/6 mice and cultured macrophages were exposed to hyperoxia as 
previously described (Patel et al., 2013). Briefly, animals were placed in microisolator 
cages (Allentown Caging Equipment, Allen-town, NJ, USA), which were kept in a 
Plexiglas chamber (BioSpherix, Lacona, NY, USA) and exposed to ≥95% O2 for up to 
48 h. The exposure of murine macrophage RAW 264.7 cells was conducted in 
humidified Plexiglas chambers (Billups-Rothenberg, Del Mar, CA, USA), flushed with 
95% O2/5% CO2 at 37°C for 24 h. An oxygen analyzer (MSA; Ohio Medical 
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Corporation, Gurnee, IL, USA) was used to monitor the O2 concentration in the 
chamber. 
2.4. Bronchoalveolar Lavage and Protein Quantification 
Murine bronchoalveolar lavage (BAL) fluid was obtained as described previously 
(Patel et al., 2013). Briefly, mice were anesthetized by an intraperitoneal injection of 
sodium pentobarbital (75 mg/kg). After a 1- to 2-cm incision was made on the neck, 
the trachea was dissected, and a 20-gauge × 1.25-inch intravenous catheter was 
inserted caudally into the lumen of the exposed trachea. The lungs were gently 
lavaged twice with 1 mL sterile, nonpyrogenic phosphate-buffered saline (PBS) 
solution (Mediatech, Herndon, VA, USA) containing a cocktail of protease and 
phosphatase inhibitors (Thermo Pierce Scientific). BAL samples were centrifuged at 
200 x g at 4˚C for 5 minutes, and the resultant supernatants were stored flash frozen 
in liquid nitrogen and then stored in a freezer at −80°C. Total protein content in BAL 
was determined by using the Pierce Bicinchoninic acid (BCA) assay Kit (Thermo 
Fisher, Waltham, MA) as per the manufacturer’s instructions. 
2.5. Quantitative Bacteriology 
Lung homogenate and BAL were serially diluted, and the viable bacterial counts were 
determined using a colony formation unit (CFU) assay by plating onto Pseudomonas 
Isolation Agar (Difco, Sparks, MD), and incubating at 37˚C for 18 h. 
2.6. Assay for Oxidative Stress and Antioxidant Potential 
Oxidative stress was determined by measuring the oxidation–reduction potential 
(ORP) using the RedoxSYS Diagnostic System (Luoxis Diagnostics, Inc., Englewood, 
CO). Lung homogenate was evaluated for its oxidative-reduction potential (ORP) 
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reported in millivolts (mV) and the capacity of the ORP (cORP) also known as the 
antioxidant potential measured in µcoloumbs (µC) at room temperature, using the 
protocol provided by the manufacturer. 
2.7. Measurement of SOD1 Activity 
RAW 264.7 cells were seeded in 6-well plates, exposed to hyperoxia, and treated as 
with GAT107 (3.3 µM) for 24h.  After 24h, cells were washed 3x in PBS and lysed with 
cell lysis buffer (Cell Signaling Technology, Danvers, MA) that contained Halt protease 
and phosphatase inhibitor cocktail (Thermo Fischer, Waltham, MA). The total protein 
content of cell lysate was determined by using the Pierce Bicinchoninic acid (BCA) 
assay Kit (Thermo Fisher, Waltham, MA) as per the manufacturer instructions. Equal 
amounts of total protein from non-denatured samples were loaded onto 12% native-
PAGE and separated at 100V at 4˚C for 90 minutes. Native-PAGE gels were then 
washed with 3x distilled water and then incubated with 2.43 mM nitrotetrazolium 
blue (Acros Chemical), 2.85 µM riboflavin (Sigma), and 28 mM TEMED (GE 
Healthcare) for 20 minutes, protected from light, and at room temperature, as 
described (Beauchamp and Fridovich, 1971). After 20 minutes, gels were placed on a 
light box and allowed to develop. The presence of achromatic bands represents the 
inhibition of the reduction of nitro tetrazolium blue by the SOD1 enzymatic and was 
detected by Bio-Rad ChemiDoc.  
2.8. 2’,7’-Dichlorofluorescin diacetate (DCFH-DA) reactive oxygen species 
(ROS) detection assay 
RAW 264.7 cells were seeded in quadruplicate in 96-well black wall, clear bottom 
plates, exposed to hyperoxia, and treated as previously described. After 24 h, cells 
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were analyzed using the DCFH-DA assay (Cell Biolabs, San Diego, CA), according to 
manufacturer instructions. In brief, cells were incubated with 1 mM DCFH-DA for 30 
minutes at 37˚C, then washed three times with warm PBS. The presence of total 
intracellular DCF (an indicator for ROS levels) was determined by lysing cells, as 
described previously (Patel 2020), and measuring a green fluorescent signal at 
480/530nm, using a Biotek Synergy LX multimode reader (Winooski, Vermont, USA). 
DCF relative fluorescent units were then reported as a percent relative to the 21% O2 
exposure group (normoxic or control group).  
2.9. Phagocytosis Assay and Assessment of Actin Stress Filament 
Formation 
The phagocytosis assay was performed as previously described, with minor 
modifications (Morrow et al., 2007; Sitapara et al., 2014). Briefly, RAW 264.7 cells or 
BMDMs were seeded in 24-well plates and allowed to adhere for 6 h followed by 
exposure to 95% O2 in the absence or presence of GAT107 (3.3 µM) for 24 h. RAW 
264.7 cells were incubated at 37˚C for 1 h with opsonized FITC-labeled latex beads 
(Polysciences, Warrington, PA) at a ratio of 100 : 1 (beads : cell). Macrophages were 
incubated with 0.04% Trypan blue in PBS for 10 minutes to quench the beads that 
were not internalized by the macrophages. To visualize the uptake of FITC-labeled 
latex beads, macrophages were fixed with 4% paraformaldehyde for 10 minutes, 
washed with PBS, and stained with 4′,6-diamidino-2-phenylindole (DAPI, Molecular 
Probes, Eugene, OR). To visualize the cell cytoskeleton, cells were stained with 
rhodamine phalladoin (Molecular Probes, Eugene, OR). The phagocytosis or uptake 
of the beads was assessed visually using an Evos Fluorescent Microscope (Thermo 
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Fischer, Waltham, MA) followed by counting 200 individual macrophages per well in 
duplicates from three independent experiments by a blinded person for each 
experimental group. To assess the hyperoxia-induced modification of actin 
polymerization, a modified experiment method was used (O’Reilly et al., 2003). Using 
the fluorescent micrographs obtained from the above phagocytosis assay, a Fiji 
ImageJ analysis (version 2.0) with the JACoP plugin was used to determine a Mander’s 
Correlation Coefficient using thresholds for the amount of phalladoin signal 
associated with the DAPI signal. This value was converted to percentage to estimate 
the amount of polymerized F-actin and stress filament formation.    
2.10. Protein Carbonyl Formation 
The amount of total protein oxidation and carbonyl formation was determined by 
using a commercially available Oxidized Protein Western Blot Kit (Abcam, 
Cambridge, UK) based on the manufacturer instructions. Equal amounts of whole cell 
lysate from three to four independent experiments were subjected to a protein 
carbonyl derivatization with 2,4-dinitrophenylhydrazone (DNP-hydrazone) in the 
presence of DNP-hydrazine or left unreacted as a negative control. The samples were 
separated by 12% SDS-PAGE and transferred to PVDF membranes. The membranes 
were washed and blocked in 5% milk/TBST solution. Next, membranes were washed 
and incubated with secondary anti-DNP antibody, washed, and the immunoreactive 
DNP bands were detected using enhanced chemiluminescence (ECL) reagents (Pierce 
Thermo Scientific) by a Bio-Rad ChemiDoc XRS+ system (Biorad, Hercules, CA). 
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2.11. Western Blot Analysis  
For intracellular protein analysis, cells were washed 3x in PBS and lysed with cell lysis 
buffer (Cell Signaling Technology, Danvers, MA) that contained Halt protease and 
phosphatase inhibitor cocktail (Thermo Fischer, Waltham, MA). The total protein 
content of cell lysate was determined by using the Pierce Bicinchoninic acid (BCA) 
assay Kit (Thermo Fisher, Waltham, MA) as per the manufacturer instructions. 
Samples were loaded onto 12% or 15% SDS–polyacrylamide gels (Bio-Rad, Hercules, 
CA) and transferred to Immobilon-P membranes (Millipore, Bedford, MA). 
Nonspecific binding sites on the membrane were blocked by incubating the 
membrane with either 5% nonfat dry milk (Bio-Rad, Hercules, CA) in Tris- buffered 
saline (TBS) containing 0.1% Tween 20 (TBST) for 1h at room temperature. 
Subsequently, membranes were washed three times with TBST and incubated 
overnight at 4˚C with anti-HO-1 (1:1000, #ab13248, Abcam, Cambridge, UK), anti-
MnSOD (1:1000, #AD-SOD-110, Enzo, New York, NY), and anti-pan-actin (1:1000, 
#8456, Cell Signaling) antibodies diluted in 5% nonfat dry milk in TBST. After three 
washes with TBST, the membranes were incubated with goat anti-rabbit horseradish 
peroxidase–coupled secondary antibody (1:5,000; GE Healthcare, Chicago, IL) for 1 h 
at room temperature. Subsequently, membranes were washed three times again with 
TBST and the immunoreactive proteins were visualized using the SuperSignal West 
Pico Plus Chemiluminescent Substrate (Thermo Fisher, Waltham, MA) per the 
manufacturer instructions. The images were developed using Bio-Rad ChemiDoc XRS 
(Bio-Rad, Hercules, CA). Immunoreactive bands were quantified using ImageJ 
software (version 2.0.0). 
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2.12. Nrf2 Analysis 
Nrf2 activation was determined by determining the amount of immunofluorescent 
Nrf2 nuclear colocalization. RAW 264.7 cells were seeded and treated as described in 
the DCFH-DA experiment. After 24h, cells were permeabilized 0.1% Triton X-100 
(Millipore Sigma, St. Louis, MO) made in PBS, blocked 10% goat serum (Millipore 
Sigma) in PBS, and incubated with anti-Nrf2-antibody (donated by Dr. Ed Schmidt of 
Montana State University) overnight. Cells were washed and immunoreacted with 
AlexaFluor488 (Pierce Thermo Scientific). Fluorescent micrographs were captured 
using an Evos fluorescent microscope. The images were analyzed for the amount of 
Nrf2 localized in the nucleus using a Mander’s Correlation Coefficient with thresholds 
as described above in the actin stress filament formation (see Section 2.9). The 
amount of Nrf2 signal located within the same signal as the nucleus was used as a 
marker of Nrf2 activation. The Mander’s correlation coefficient were then reported 
as a percent of total Nrf2 signal within the nucleus.   
2.14. Measurement of Mitochondrial Membrane Potential and 
Mitochondrial Superoxide  
RAW 264.7 cells were seeded in 96-well black wall, clear bottom plates, exposed to 
hyperoxia, and incubated with and without GAT107 (3.3 µM) as previously described. 
Macrophage mitochondrial membrane potential was determined by using the 
tetramethylrhodamine ethyl ester (TMRE) Mitochondrial Membrane Potential Assay 
Kit (Abcam, Cambridge, UK) as per the manufacturer’s instructions. In brief, after the 
24 h incubation period, cells were incubated with 1 µM of TMRE for 20 minutes at 
37˚C. Prior to TMRE, a negative control group for mitochondrial membrane 
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polarization was generated by incubating the cells with 20 µM of the carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP) uncoupling reagent for 15 minutes at 
37˚C. After incubation with TMRE, cells were gently washed with PBS containing 0.2% 
BSA and fluorescence detected at 549nm/570nm using a Synergy LX multimode 
reader. In another set of experiments, macrophages were cultured and treated as 
described for the TMRE assay and then incubated with MitoTracker Green FM 
(Thermo Fisher, Waltham, MA) to determine the mitochondrial density as per the 
manufacturer’s instructions. MitoTracker Green FM accumulates in mitochondria, 
independent of the membrane potential, and serves as a marker for total 
mitochondrial density. The relative fluorescent levels of MitoTracker Green FM in 
each condition group were then normalized to the 21% O2 control group, and these 
values were used to normalize the percent TMRE relative fluorescence values, which 
was represented as a bar graph as the percent TMRE / MitoTracker Green to 
demonstrate the mitochondrial membrane polarization status. For the measurement 
of mitochondrial superoxide levels, after 24h of incubation, macrophages were 
incubated with 5 µM of the MitoSOX reagent (Invitrogen, Carlsbad, CA) for 10 minutes 
at 37˚C and washed three times with 37˚C PBS as per the manufacturer’s instructions. 
The presence of mitochondrial superoxide was detected using a Synergy LX 
multimode reader at the settings of 510 / 580 nm.  
2.15. Measurement of MnSOD Activity 
After 24 h of hyperoxic exposure and incubation with GAT107 (3.3µM), RAW 264.7 
macrophage cell lysates were prepared as described above (Section 2.11). Equal 
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amounts of protein were tested for the enzymatic activity of MnSOD using a 
Superoxide Dismutase (SOD) Colormetric Activity Kit (Thermo Fisher) as per 
manufacturer’s instructions. In brief, non-mitochondrial iron SOD (FeSOD) and 
copper zinc SOD (CuZnSOD) were inhibited by incubating the cell lysate with cyanide. 
Cell lysates containing cyanide were then incubated with a xanthine oxidase reagent 
that generates superoxide in the presence of oxygen. The amount of superoxide not 
dismutated into hydrogen peroxide by MnSOD is then reacted with a nitro blue 
tetrazolium blue reagent to yield a yellow color. This chromogenic reaction product 
was read at 450 nm on a Synergy LX multimode reader (Biotek, Winooski, VT). The 
results were compared to a standard curve generated by using bovine erythrocyte 
SOD (produced without the addition of cyanide) and normalized to total protein 
concentrations. 
2.16. Immunoprecipitation and Immunodetection 
RAW 264.7 cells were exposed to 24h of hyperoxia and incubated with GAT107 (0 or 
3.3 µM) as described above. Cell lysates were collected, and protein content 
determined as described for the Western blot analysis (section 2.11). MnSOD was co-
immunoprecipitated from cell lysates using the Pierce Direct Magnetic IP/Co-
Immunoprecipitation Kit (Thermo Scientific, Waltham, MA) using a polyclonal anti-
MnSOD antibody (Enzo, New York, NY) per the manufacturer’s instructions. After 
immunoprecipitation, samples were immediately subjected to SDS-PAGE and 
Western blot analysis as described above (section 2.11). Western blot analysis was 
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conducted as described above using anti-MnSOD antibody (1:1000, Enzo, New York, 
NY) and monoclonal anti-glutathione antibody (1:1000, Virogen, Watertown, MA). 
2.17. Statistical Analysis 
The statistical analyses were carried out using GraphPad Prism statistical software 
(version 7.0a). The results are presented as the mean ± SEM. The data were analyzed 
for statistical significance according to analysis of variance (ANOVA) with Dunnett’s 
post hoc analysis. Animal survival data was analyzed by using a Kaplan-Meier curve. 
Glutathionylation versus MnSOD activity data was analyzed using a correlation 
analysis using a two-tail Pearson Correlation Coefficient test. A 95% confidence 





3. FIGURES AND FIGURE LEGENDS 
 
Figure 1. Systemic administration of GAT107 increases survival in mice with 
exposed to hyperoxia and challenged with PA lung infection 
Male C57BL/6 were exposed to >95% O2 for 72 h and then inoculated with PA (0.1 x 108 
CFUs / mouse) and then returned to 21% O2 after inoculation. Mice were randomized to 
receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal injection every 12 h 
starting at hour 24 of hyperoxia. After mice were inoculated, animal survival was 
monitored and recorded every hour for 24 h and represented above as a Kaplan-Meier 
curve. Data were analyzed using the log-rank Mantel-Cox test; *p < 0.05 compared to 
hyperoxia exposed vehicle treated control group (n = 5 - 10 mice / group). 
 
  




























Figure 2. Systemic administration of GAT107 improves bacterial clearance in mice 
exposed to 48 h hyperoxia and challenged with PA infection.  
Male C57BL/6 were exposed to >95% O2 (hyperoxia) for 48 h and then inoculated with 
PA (0.1 x 108 CFUs / mouse) and then returned to 21% O2 after inoculation. Mice were 
randomized to receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal 
injection every 12 h starting at hour 24 of hyperoxia. BAL and lung tissue were harvested 
24 h after inoculation. Viable bacteria in the airways and lungs were quantified by plating 
serials dilutions of (A) BAL and (B) lung homogenate and expressed as the log of colony 
forming units (CFUs) per mL. Data represent the mean ± SEM from n = 6-7 mice per 
group. Statistical differences were determined between all groups and indicated a **** p 










































































Figure 3. GAT107 restores hyperoxia-compromised macrophage phagocytic 
function in a macrophage cell line and in primary macrophages.  
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar) 
with or without GAT107 (grey bars). Cells were incubated with FITC-labeled minibeads 
for 1 h and stained to visualize the cytoskeleton and nucleus. Immunofluorescent 
micrographs show the phagocytosed beads (green), cytoskeleton (red), and nucleus 
(blue) of (A) RAW 264.7 cells and (B) BMDMs. The bar graphs represent the 
quantification of phagocytosis of at least 200 cells was represented as a percent beads 
phagocytosed. Quantification of phagocytosis for (C) RAW 264.7 and (D) BMDMs cells. 
Each value represents the mean ± SEM of three independent experiments for each group. 
Statistical differences were determined between all groups and indicated a **** p < 
































































21% O2 95% O2 95% O2
3.3µM GAT1070µM GAT107
21% O2 95% O2 95% O2







Figure 4. GAT107 Mitigates Hyperoxia-Induced Actin Oxidation and Alterations in 
Polymerization.  
RAW 264.7 were either exposed to 21% O2 or 95% O2 (hyperoxia) with or without 
GAT107. After 24 h, (A) the actin polymerization was analyzed using fluorescent 
micrographs obtained as described in the Phagocytosis Assay in the methods, and the 
ratio of actin to the nuclei were reported as a percent of non-overlapping signals obtained 
from ImageJ’s co-localization analysis plugin and computation of the Manders’ 
Correlation Coefficient. Each value represents mean ± SEM of three independent 
experiments for each group. Statistical differences were determined between all groups 
and indicated a **** p < 0.0001, ** p < 0.01 compared to the hyperoxia exposed vehicle 
control group. (B) Macrophages were then also analyzed for total protein carbonylation 
by oxidized protein Western blot and the 43kD immunoreactive band was used to 
evaluate the extent of actin oxidation (as indicated by the arrow) for 3 – 4 independent 

















































Figure 5. Systemic administration of GAT107 attenuates oxidative stress via 
enhancement of total lung antioxidant potential.  
Male C57BL/6 mice were exposed to 95% O2 (hyperoxia) for 48 h and then inoculated 
with PA (0.1 x 108 CFUs / mouse), and then returned to 21% O2 after inoculation. Mice 
were randomized to receive GAT107 (0 or 3.3 mg/kg) administered via intraperitoneal 
injection every 12 h starting at hour 24 of hyperoxia. Lung tissue was harvested 24 h after 
inoculation. Lung homogenate was analyzed for (A) oxidative-reduction potential (ORP) 
measured in millivolts (mV) and (B) capacity of the ORP or total antioxidant potential 
(cORP) measured in µCoulombs (µC) by the RedoxSys System. Data represent the mean 
± SEM of two-independent experiments from n = 4 mice per group. Statistical differences 
were determined between all groups and indicated a *p < 0.05 compared to the hyperoxia 




































































Figure 6. GAT107 Attenuates Hyperoxia-Induced Oxidative Stress by Restoring 
Hyperoxia-Compromised SOD1 Function.  
RAW 264.7 were either exposed to 21% O2 (room air) (white bar) or 95% O2 (hyperoxia) 
(black bar) with or without GAT107 (grey bars). After 24 h, (A) macrophages were 
subjected to DCFH-DA Assay and the amount of fluorescent DCF signal within 
macrophages was determined spectrophotometrically and reported as a percent relative 
to the room air control to evaluate oxidative stress. (B) SOD1 activity was determined by 
gel-based nitro tetrazolium blue gel assay as described in the methods section and (C) 
reported as a fold change compared to the room air control group. Each value represents 
mean ± SEM of three independent experiments for each group. Statistical differences 
were determined between all groups and indicated a **** p < 0.0001, *** p < 0.001, ** p 






























































































Figure 7. GAT107 Activates the Nrf2/HO-1 Antioxidant Pathway.  
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar) 
with or without GAT107 (grey bars).After 24h, macrophages were fixed, permeabilized, 
blocked, and incubated with a polyclonal anti-Nrf2-antibody overnight, then conjugated 
to AlexaFluor 488, and then counterstained with DAPI to visualize the nucleus. (A) 
Immunofluorescent micrographs were subjected to ImageJ co-localization analysis and 
pseudo colored to determine the amount of Nrf2 signal (red) localized to the nucleus 
(green) using the Manders’ Correlation Coefficient. (B) The bar graphs represent the 
percent amount of total Nrf2 signal localized to the nuclear region. Under the same 
experimental conditions, macrophages were also analyzed for levels of heme oxygenase-
1 (HO-1) and actin in whole cell lysate by Western blot analysis. (C) The representative 
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bands normalized to actin. Each value represents the mean ± SEM of two to three 
independent experiments for each group. Statistical differences were determined 
between all groups and indicated a **** p < 0.0001, * p < 0.05 compared to the hyperoxia 





















Figure 8. GAT107 restores hyperoxia-compromised macrophage mitochondrial 
integrity and mitochondrial oxidative stress.  
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar) 
with or without GAT107 (grey bars). After 24 h, (A) macrophage mitochondrial integrity 
was measured by tetramethylrhodamine, ethyl ester (TMRE) mitochondrial membrane 
potential assay and normalized to MitoTracker Green. TMRE accumulates in 
mitochondrial directly proportional to the mitochondrial membrane potential, while 
MitoTracker Green localizes to mitochondria based on mitochondrial mass, not the 
polarization status. (B) Macrophages were then analyzed for mitochondrial superoxide 
using the MitoSOX dye after hyperoxia exposure. Each value represents mean ± SEM of 
three independent experiments for each group. Statistical differences were determined 
between all groups and indicated a **** p < 0.0001, ** p < 0.01 compared to the 
























































































Figure 9. GAT107 attenuates hyperoxia-compromised MnSOD activity.  
RAW 264.7 were either exposed to 21% O2 (room air) (white bar) or 95% O2 (hyperoxia) 
(black bar) with or without GAT107 (grey bars). After 24 h, whole cell lysates were 
analyzed for total MnSOD levels by Western blot for MnSOD. (A) Representative Western 
blots for MnSOD and actin and (B) the densiometric analysis of Western blot bands. (C) 
RAW 264.7 cell lysate was used to determine MnSOD activity using a SOD activity kit in 




































































































SEM of three independent experiments for each group. #p < 0.05, versus the room air 
control group; Statistical differences were determined between all groups and indicated 
a **** p < 0.0001, *** p < 0.001 compared to the hyperoxia exposed vehicle treated 
control group. 
 




Figure 10. The hyperoxia-induced glutathionylation of MnSOD is significantly 
decreased by GAT107.  
RAW 264.7 were either exposed to 21% O2 (white bar) or 95% O2 (hyperoxia) (black bar) 
with or without GAT107 (grey bars). After 24 h, whole cell lysates were co-
immunoprecipitated for MnSOD. (A) Representative Western blots for 
immunoprecipitated MnSOD and conjugated GSH. (B) Densiometric analysis for 
immunoreactive GSH and MnSOD bands were determined and the ratio of GSH to MnSOD 
was reported as a percentage on the bar graph. Each value represents the mean ± SEM of 
3-4 independent experiments for each group. Statistical differences were determined 
between all groups and indicated a **** p < 0.0001, ** p < 0.01 compared to hyperoxia 





























































































respective corresponding percentage of MnSOD glutathionylation and presented as a 
correlation plot. Each value on the correlation plot represents individual sample data 
points from 3 – 4 independent experiments. The measure of strength between the X and 
Y variables was determined by a two-tailed Pearson-correlation coefficient, which 






Figure 11. Proposed pathway of the efficacy of GAT107 on macrophages to alleviate 
the bacterial burden in hyperoxia-compromised mice with PA lung infection.  
The prolonged exposure to hyperoxia (O2) induces the accumulation of reactive oxygen 
species (ROS) in the cytosol and mitochondria of macrophages. Macrophage 
mitochondrial normally generate superoxide (O2-) as a byproduct of the electron 
transport chain, which is rapidly dismutated by manganese superoxide dismutase 
(MnSOD) into hydrogen peroxide (H2O2). However, under hyperoxic conditions, high 
concentrations of oxygen contribute to both mitochondria dysfunction and 
mitochondrial superoxide accumulation. Sustained high levels of superoxide 
compromise MnSOD activity via promoting cysteine glutathionylation, which contributes 
to increasing the total level of mitochondrial superoxide. In addition, cytosolic 
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antioxidant defense systems (e.g. SOD1) are also suppressed during the prolonged 
exposure to hyperoxia. High levels of ROS accumulate in the cytosol, which oxidize F-actin 
filaments, resulting in impaired macrophage phagocytic functions. Together, both 
mitochondrial dysfunction and F-actin oxidation contribute to the impaired bacterial 
clearance functions of macrophages, resulting in the increased bacterial burden in the 
airways of mice with PA lung infection and higher mortality rates. Treatment with 
GAT107 to macrophages activates α7nAChR and results in the activation of the Nrf2. 
GAT107-induced Nrf2 activation upregulates heme oxygenase-1 (HO-1). Upregulated 
levels of HO-1 then contribute to alleviating the oxidative burden in the mitochondria 
and the cytosol. GAT107 then mediates the reduction in mitochondrial superoxide 
levels, reduced MnSOD cysteine glutathionylation, and ameliorates mitochondrial 
dysfunction. Together with alleviating F-actin oxidation via enhancing the 
antioxidant response (HO-1 and SOD1) and improved mitochondrial functions, 
GAT107 attenuates hyperoxia-induced macrophage phagocytic dysfunction. As such, 
GAT107 improves the bacterial clearance of PA lung infection and increases the rate 





4.1. Systemic administration of GAT107 increases survival in mice 
exposed to hyperoxia and challenged with PA lung infection 
The prolonged exposure to hyperoxia is the critical mediator for the increased rates 
of mortality in patients with pulmonary infection (Chastre and Fagon, 2002; Rello, 
2005; Spalding et al., 2017; M. Wang et al., 2019). To ascertain whether GAT107 
administration to hyperoxia-compromised mice with Pseudomonas aeruginosa (PA) 
lung infection could improve animal survival rates, mice were initially exposed to 72 
h of 95% O2. During the 72 h of hyperoxia exposure, mice were administered 
intraperitoneally with GAT107 3.3 mg/kg or vehicle control as described previously 
above (section 2.2). As demonstrated in Figure 1, mice which remained in hyperoxic 
conditions had significantly higher mortality rates (20% of mice survived, p < 0.05) 24 h 
after challenge with bacterial lung infection when compared to mice that remained in 
room air (21% O2) conditions (100% of mice survived). In mice administered with 
GAT107 (3.3 mg/kg), subjected to hyperoxic conditions, and challenged with PA lung 
infection, there was a significant improvement of mouse mortality rates (37.5% of mice 
survived, p < 0.05) when compared to hyperoxia control group. In addition, 
administration of GAT107 increased the mean survival time to 18.25 hours versus just 
15.25 hours in the hyperoxia control group. Therefore, these data suggest that GAT107 
improves animal survival of hyperoxia-compromised mice with PA lung infection. 
4.2. Systemic administration of GAT107 improves bacterial clearance in 
mice exposed to 48 h hyperoxia and challenged with PA infection. 
The prolonged exposure to hyperoxia can compromise the ability of subjects to clear 
bacterial lung infections (Patel et al., 2016, 2013; Sitapara et al., 2014). To determine if 
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GAT107 can restore the compromised clearance of bacteria in the lungs, we subjected 
mice to hyperoxia exposure, administered intraperitoneally (i.p.) of GAT107 3.3 mg/kg 
and instilled PA into lungs (i.e., bacterial challenge). As shown in Figure 2, mice that 
received prolonged exposure to 95% O2 (i.e., hyperoxia) and were challenged with PA-
induced lung infection (vehicle control group), had significantly higher levels of bacterial 
colonies in their airways (7.81 ± 0.24 log CFUs/mL, p < 0.0001) and lung tissue 
homogenate (7.68 ± 0.07 log CFUs/mL, p < 0.0001) compared to mice that remained 
at 21% O2 (3.24 ± 0.15 log CFUs/mL in airways and 3.62 ± 0.35 log CFUs/mL in lung 
tissue homogenate). The mice that received 3.3 mg/kg i.p. of GAT107 (3.93 ± 0.52 
CFUs/mL in airways and 4.49 ± 0.54 log CFUs/mL in lung tissue homogenate) had 
significantly lower levels of bacterial colonies in their airway fluids and lung tissue 
homogenate compared to the vehicle control group (****p < 0.0001). GAT107 
administration had no significance difference when compared to room air control 
animals. These data indicate that GAT107 significantly decreases the lung bacterial 
burden in a mouse model of VAP. 
4.3. GAT107 restores hyperoxia-compromised macrophage phagocytic 
function in a macrophage cell line and in primary macrophages 
The decreased ability to clear bacterial lung infections in subjects compromised by 
hyperoxia exposure, is in part mediated by the impaired innate immune functions of 
macrophages. To determine whether GAT107 can restore hyperoxia-compromised 
macrophage function, RAW 264.7 and primary bone marrow-derived macrophages 
(BMDMs) were exposed to >95% O2 (hyperoxia) for 24h and incubated with either 
3.3 µM GAT107 or vehicle control (DMSO). The phagocytotic function of RAW 264.7 
cells exposed to hyperoxia was significantly decreased (66.1 ± 2.5%, p < 0.0001) 
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compared to cells that remained at 21% O2 (100 ± 0%). Hyperoxia-compromised 
phagocytosis was significantly attenuated by 3.3 µM GAT107 (86.3 ± 4.7%, p < 
0.0001) compared to the vehicle control group (65.08 ± 2.53%) (Figure 3A and C). 
Furthermore, these effects were also replicated in primary BMDMs, where after 
exposure to 24h of hyperoxia, their phagocytic activity was significantly decreased 
(33.2 ± 5.3%, p < 0.0001), compared to macrophages that remained at 21% O2 (100 
± 0%). GAT107 significantly increased the phagocytotic activity of BMDMs exposed 
to hyperoxia (105 ± 13.9%, p < 0.001) compared to the vehicle control group (35.39 
± 3.9%) (Figure 3B and D). GAT107 incubation in hyperoxia-compromised 
macrophages showed no statistically significant difference when compared to cells 
that remain in room air control conditions. These results suggest that in vitro, GAT107 
can attenuate the hyperoxic-induced decrease in macrophage phagocytic activity.  
4.4. GAT107 Attenuates Hyperoxia-Induced Actin Oxidation and 
Alterations in Polymerization. 
Exposure to macrophages with hyperoxia can result in oxidative post-translational 
modification to F-actin filaments that are critical for macrophage innate immune 
functions (Morrow et al., 2007; O’Reilly et al., 2003). To determine if GAT107 can 
attenuate hyperoxia-induced actin oxidation and altered actin polymerization, RAW 
264.7 macrophages were exposed to 24 h of 95% O2 (hyperoxia) and incubated with 3.3 
µM  GAT107. The fluorescent microscopic analysis and quantification of F-actin stress 
fiber formation, similar to previous studies (Morrow et al., 2007; O’Reilly et al., 2003), 
indicated that macrophages exposed to hyperoxia had significantly higher amounts of 
stress actin filament formation as indicated by an increased phalladoin/DAPI ratio (91.25 
± 1.09%, p < 0.0001), compared to cells that remained at room air (81.05 ± 
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1.07%)(Figure 4A). Furthermore, 3.3 µM GAT107 significantly decreased stress actin 
formation produced by hyperoxia (83.45 ± 1.53%, p < 0.01), compared to the vehicle 
control group (89.53 ± 1.34%). GAT107 incubation to hyperoxia-compromised 
macrophages had no statistical difference when compared to cells that remained in 
room air control conditions. Furthermore, macrophages exposed to hyperoxia had 
increased total protein oxidation compared to the macrophages that remained in 
room air, and this was decreased by incubation with 3.3 µM GAT107 (Figure 4B). The 
proteins that migrated to approximately 43 kD were used as an indicator of actin 
oxidation. Based on the 43 kD marker proteins, we observed the same protein 
oxidation trend, suggesting that GAT107 also reduces the amount of hyperoxia-
induced actin oxidation. Overall, these results indicate that GAT107 attenuates 
hyperoxia-induced alterations in actin polymerization by reducing the oxidation of 
total protein and actin.  
4.5. The systemic administration of GAT107 attenuates hyperoxia-
induced oxidative stress and increases the total lung antioxidant 
potential 
Previous studies have shown that hyperoxia-induced oxidative stress mediates the 
decreased bacterial clearance functions of mice, which can be ameliorated when 
subjects are administered antioxidants, like ascorbic acid (Patel et al., 2016; Sitapara 
et al., 2020). To determine if GAT107 mitigates excessive lung oxidative stress in mice 
exposed to 95% O2 (hyperoxia) and challenged with PA lung infection, the oxidative 
redox potential (ORP) and the lung antioxidant potentials (cORP) were determined. 
As shown in Figure 5, mice subjected to 95% O2 had significantly higher oxidative-
reduction potentials (298 ± 44.3 mV, p< 0.05) and lower antioxidant potentials (0.16 
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± 0.05 µC, p < 0.05), compared to mice that remained at 21% O2 (204.26 ± 7.5 mV and 
0.27 ± 0.03 µC, respectively). Indeed, the i.p. administration of 3.3 mg/kg GAT107 
significantly attenuated the hyperoxia-induced increased lung oxidative-reduction 
potential (162.36 ± 22.1 mV, p<0.05), and increased the total antioxidant potential 
(0.47 ± 0.09 µC, p < 0.05), compared to the vehicle control group. GAT107 ameliorated 
hyperoxia-induced increased lung homogenate ORP to a level that showed no 
statistically significant difference when compared to animals that remained in room 
air control conditions. These data indicate that GAT107 attenuates lung oxidative 
stress by increasing the total antioxidant potential. 
4.6. GAT107 Attenuates Hyperoxia-Induced Oxidative Stress by Restoring 
Hyperoxia-Compromised SOD1 Function 
The prolonged exposure to hyperoxia induces oxidative stress and compromises the 
innate immune functions of macrophages, which can be attenuated by the treatment 
with antioxidants, like ascorbic acid and superoxide dismutase (Arita et al., 2007; 
Morrow et al., 2007; Patel et al., 2020). To determine if hyperoxia-induced oxidative 
stress is attenuated by GAT107, RAW 264.7 cells were exposed >95% O2 (hyperoxia) 
and incubated with 3.3 µM GAT107. The prolonged exposure to hyperoxia 
significantly increased the total intracellular ROS levels (305.79 ± 20.21%, p < 
0.0001), compared to macrophages that remained at 21% O2 (100 ± 0%) (Figure 6A). 
GAT107 significantly decreased total intracellular ROS levels (231.05 ± 5.75%, p < 
0.0001), compared to vehicle control (353.28 ± 27.81%) (Figure 6A). The prolonged 
exposure to hyperoxia significantly compromises SOD1 activity (45.59 ± 8.71%, p < 
0.001), compared to cells that remained at 21% O2 (100 ± 0%) when compared to 
21% O2 (Figure 6B). Hyperoxia-compromised SOD1 activity was significantly 
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restored in macrophages following treatment with 3.3 µM GAT107 (84.63 ± 10.75%, 
p<0.01), compared to vehicle control (41.56 ± 7.31) (Figure 6B). These results 
suggest that hyperoxia-induced oxidative stress is decreased by GAT107, in part, by 
the restoring the hyperoxia-compromised antioxidant activity of SOD1. 
4.7. GAT107 Activates the Nrf2/HO-1 Antioxidant Pathway 
Previous studies indicate that the activation of Nrf2 can protect mice against 
hyperoxia-induced acute lung injury and macrophage dysfunction by upregulating 
enzymes involved in the antioxidant, such as heme oxygenase-1 (HO-1) (Otterbein et 
al., 1999; Reddy et al., 2009; Wang et al., 2007). To determine if GAT107 can induce 
the activation of Nrf2, macrophages were exposed to 24h of 95% O2 (hyperoxia) and 
incubated 3.3 µM GAT107. Our results indicate that under hyperoxic conditions 
(25.83 ± 7.19%), there was no significant increase in Nrf2 localization to the nucleus, 
compared to macrophages exposed to room air (21.2 ± 4.8%) (Figure 7A). However, 
GAT107 significantly increased Nrf2 nuclear localization (51.45 ± 4.08%, p <0.05), 
compared to vehicle control (31.03 ± 5.01%) (Figure 7A). Next, we determined the 
levels of the protein, HO-1 in macrophages by Western blot analysis. Under hyperoxic 
conditions (0.643 ± 0.075 AU HO-1/actin), there was a non-significant change in HO-
1 levels when compared to 21% O2 room air (0.107 ± 0.01 AU HO-1/actin) (Figure 
7B). However, the incubation of macrophages with 3.3 µM GAT107 (2.38 ± 1.91 AU 
HO-1/actin, p < 0.0001) induced a significant increase in HO-1 levels, compared to 
vehicle control (0.745 ± 0.05 AU HO-1/actin) (Figure 7B). These results suggest that 
in vitro, GAT107 induces Nrf2 and HO-1 upregulation.  
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4.8. GAT107 attenuates hyperoxia-induced mitochondrial membrane 
hyperpolarization and mitochondrial superoxide accumulation  
The exposure of macrophages to hyperoxia has been reported to produce 
mitochondrial damage (Ma Cui et al., 2018; Pagano and Barazzone-Argiroffo, 2003). 
Furthermore, mitochondrial damage has a significant inhibitory effect on 
macrophage phagocytosis (Orrenius et al., 2011). To determine if 24 h of hyperoxic 
exposure to macrophages affects mitochondrial function, the mitochondrial 
membrane potential was determined using the tetramethylrhodamine ethyl ester 
(TMRE) assay. Our results indicated that the mitochondrial membrane potential of 
macrophages exposed to hyperoxia was hyperpolarized (141 ± 13.8 %, p < 0.0001) 
compared to macrophages exposed to room air (100 ± 0%). Moreover, in this study, 
hyperoxia-induced mitochondrial hyperpolarization was significantly attenuated by 
GAT107 at 3.3 µM (62.85 ± 7.29 %, p < 0.0001) compared to vehicle control (123.5 ± 
4.6%) (Figure 8A). Additionally, the prolonged exposure to hyperoxia also 
significantly increased the mitochondrial levels of superoxide (mitoSOX) (212 ± 23 
%, p < 0.01) when compared to macrophages that remained in room air (21% O2) 
conditions (100 ± 0%) (Figure 8B). Furthermore, GAT107 treatment significantly 
decreased (147.7 ± 33.4 %, p < 0.01) hyperoxia-induced increased mitoSOX levels 
when compared to hyperoxia-compromised macrophages treated with vehicle 
control (226.3 ± 31%) (Figure 8B). Therefore, these results suggest that GAT107 
attenuates hyperoxia-induced mitochondrial membrane hyperpolarization along 
with the amelioration of hyperoxia-induced mitochondrial superoxide accumulation.  
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4.9. GAT107 Attenuates Hyperoxia-Compromised MnSOD Activity 
Under normal cellular conditions, mitochondrial superoxide is rapidly dismutated 
into hydrogen peroxide by MnSOD (Candas and Li, 2014). To determine if hyperoxia-
exposure affected total levels of MnSOD protein in macrophages, Western blot 
analysis was performed on whole cell lysates collected from RAW 264.7 cells exposed 
to 24 h of hyperoxia and incubated with 3.3 µM GAT107 (Figure 9A), as described 
previously. Interestingly, in macrophages exposed to hyperoxic conditions, there was 
a significant increase in the total levels of MnSOD protein (2.93 ± 0.18 MnSOD/actin, 
p < 0.001) when compared to cells that remained in room air control conditions (1.17 
± 0.23 MnSOD/actin). Furthermore, incubation with 3.3 µM GAT107 had no 
statistically significant effect (2.89 ± 0.13 MnSOD/actin) on hyperoxia-increased 
MnSOD protein levels when compared to the vehicle control group (2.78 ± 0.15 
MnSOD/actin). Therefore, we postulated that the significant increase in 
mitochondrial superoxide following the prolonged exposure to hyperoxia could 
result from an alteration in the activity of MnSOD.  
To determine if GAT107 modulated MnSOD activity under hyperoxic conditions, 
macrophage whole cell lysates were collected as previously described and subjected 
to a MnSOD enzyme activity kit assay. As shown in Figure 9C, macrophages exposed 
to hyperoxic conditions had a significant decrease in MnSOD activity (2.72 ± 0.11 
U/mg protein, p < 0.0001) when compared to cells that remained in room air 
conditions (3.9 ± 0.2 U/mg protein). Interestingly, incubation with 3.3 µM GAT107 
significantly increased the MnSOD activity of hyperoxia-exposed macrophages (3.26 
± 0.047 U/mg, p<0.001) when compared to macrophages treated with vehicle control 
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(2.73 ± 0.09 U/mg) (Figure 9C). Therefore, these results suggest that GAT107 
attenuates hyperoxia-compromised MnSOD function through modulating MnSOD 
activity independent of its whole cell protein levels. 
4.10. GAT107 restores MnSOD activity by inhibiting hyperoxia-induced 
MnSOD glutathionylation 
Previous studies indicate that under oxidative stress conditions, MnSOD undergoes 
post-translational modification and becomes less enzymatically active (Candas and 
Li, 2014). MnSOD activity was not dependent on whole cell MnSOD protein levels as 
GAT107 did not significantly alter MnSOD activity compared to the hyperoxia control 
group (Figure 10A). Therefore, we determined the effect of GAT107 on post-
translational modification by the reversible glutathionylation of MnSOD, which 
decreases MnSOD activity. Western blot analysis of co-immunoprecipitated MnSOD 
indicated that macrophages exposed to hyperoxia had significant higher levels of 
glutathionylated MnSOD compared those exposed to the room air control group (91.8 
± 6.7 % versus 7.6 ± 4.5 % GSH/MnSOD, p < 0.0001). Macrophages exposed to 
hyperoxia and incubated with 3.3 μM GAT107 had a significantly lower level of 
glutathionylated MnSOD compared to vehicle control (53.5 ± 7.5 % versus 91.2 ± 6.5 
% GSH/MnSOD, p < 0.01). A correlation analysis indicated a significant negative 
correlation between an increase in the glutathionylation of MnSOD and MnSOD 








We have previously shown that treatment with the α7nAChR partial-agonist, GTS-21, 
can attenuate hyperoxia-compromised bacterial clearance functions in mice with PA 
lung infection (Sitapara et al., 2014), but does not significantly improve mouse 
survival rates.  
In this study, we demonstrate that GAT107, an α7nAChR ago-PAM, significantly 
improves the survival rates of mice by attenuating hyperoxia-compromised bacterial 
clearance functions of mice. The improvement of bacterial clearance functions was 
caused by efficacy of GAT107 on attenuating hyperoxia-compromised macrophage 
functions. The hyperoxia-impaired macrophage functions were attenuated by the 
GAT107-mediated decreased oxidation of F-actin, a critical cytoskeletal component 
in macrophage phagocytosis. GAT107 protected mouse lungs and macrophages from 
the effects of hyperoxia by ameliorating hyperoxia-induced oxidative stress and 
enhancing the antioxidant response. These effects of GAT107 on macrophages were 
demarcated by improving the redox balance in mitochondria, resulting in attenuated 
mitochondrial stress and the enhanced antioxidant function of MnSOD. Interestingly, 
GAT107 modulated MnSOD activity via attenuation of hyperoxia-induced cysteine 
glutathionylation. These results suggest that GAT107 increases bacterial clearance by 
improving hyperoxia-compromised phagocytic function of macrophages via 
improving the redox balance of macrophages.  
5.1. The systemic administration of GAT107 increases survival in 
hyperoxia-compromised mice with PA lung infection 
Herein this study, we demonstrate that GAT107 administration significantly 
improves the survival rates of mice exposed to hyperoxia and then challenged with 
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PA lung infection. Since 1899, it has been previously reported that in subjects exposed 
to 100% oxygen tensions that it promotes the pathogenesis of pneumonia and lung 
injury (Smith, 1899). PA is a ubiquitous gram-negative bacterium, which is typically 
harmless, but in immunocompromised individuals, such as patients exposed to 
prolonged periods of hyperoxia, PA becomes highly opportunistic and pathogenic 
(Faure et al., 2018). The uncontrolled and elevated bacterial burden of PA in the lungs 
leads to disruption and damage to the endothelial and epithelial alveolar barriers, 
which can result in acute lung injury (ALI)/acute respiratory distress syndrome, 
leading up to multiple organ failure and death (Faure et al., 2018; Sadikot et al., 2005; 
M. Wang et al., 2019).  
A key pathological feature characterizing hyperoxia-compromised subjects with PA 
lung infection is the presence of ALI. The prolonged exposure to hyperoxia itself can 
cause hyperoxia-induced acute lung injury (HALI) characterized by increased airway 
protein content and inflammatory cell infiltration, which is mediated in part by both 
oxidative stress and the extracellular accumulation of HMGB1 (Entezari et al., 2014; 
Kallet and Matthay, 2013; Patel et al., 2020; Sitapara et al., 2020). Previously, it has 
been demonstrated that activation of the cholinergic anti-inflammatory pathway can 
protect against shock-induced death and lung injury in dogs by reducing 
vasopermeability and TNF-α and Il-1 levels (Hu et al., 2014). Specifically, treatment 
with GTS-21 has been demonstrated to have a protective effect against both 
hyperoxia and LPS-induced lung injury through mitigating the pro-inflammatory 
response of macrophages (Sitapara et al., 2020, 2014; J. Wang et al., 2019). Therefore, 
based on the data presented in this study and others, the treatment of subjects that 
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receive hyperoxic oxygen therapy, such as those under mechanical ventilation, with 
activators of the cholinergic anti-inflammatory pathway like GAT107, may be 
effective in alleviating lung injury and subsequently improve survival rates. 
Importantly, length of mechanical ventilation days is directly associated with the 
incidence of mortality in ICU patients (Pranikoff et al., 1997). Thus, the development 
of treatments, like GAT107, that reduce pulmonary inflammation, lung 
permeability/edema, and lung injury, may be a potential therapeutic intervention to 
improve lung functions and allow clinicians to better use conservative oxygen 
strategies and/or reduce the amount of days a subject requires mechanical 
ventilation (Jaffal et al., 2017). However, future studies are needed to confirm 
whether the ability of GAT107 to increase the survival rates of hyperoxia-
compromised mice with PA lung infection is through ameliorating inflammatory lung 
injury and modulating levels of HMGB1.  
5.2. GAT107 Attenuates the Hyperoxia-Compromised Bacterial Clearance 
Functions of Mice with PA lung infection 
As previously mentioned, high levels of PA in the lungs is damaging to pulmonary 
tissue, which can result in increased mortality rates in ventilated patients (Faure et 
al., 2018; Sadikot et al., 2005; M. Wang et al., 2019). As shown in Figure 2, mice 
subjected to the prolonged exposure to hyperoxia and challenged with PA lung 
infection have an impaired capacity to clear PA in the airways and lung tissue, and 
administration of GAT107 can significantly attenuate this dysfunctional host defense 
response. As compared to our previous findings where 4 mg/kg i.p. of GTS-21 was 
given three times a day under the same experimental paradigm (Sitapara et al., 2014), 
the twice daily administration of 3.3 mg/kg i.p. of GAT107 produced a ten-fold 
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improvement in the clearance of bacteria by the mice. Since agonists of α7nAChR are 
prone to receptor desensitization, we hypothesized that the ago-PAM properties of 
GAT107 may allow for lower and less frequent dosing to produce a similar magnitude 
of bacterial clearance, but a more detailed pharmacological evaluation will be 
required to verify our hypothesis. Nevertheless, these improved clinically relevant 
outcomes are important because as mentioned previously, patients receiving oxygen 
therapy will be exposed to hyperoxia for extended periods of times, which can 
compromise innate immune responses needed to clear bacteria, increasing the 
incidence of hospital-acquired infections (Kallet and Branson, 2016; Koenig and 
Truwit, 2006; Mach et al., 2011; Six et al., 2016). Moreover, other investigations have 
also utilized direct vagus nerve stimulation, which activates the cholinergic anti-
inflammatory α7nAChR’s, and has been shown to improve the bacterial clearance 
functions and survival rates of subjects with sepsis (Borovikova et al., 2000; Huston 
et al., 2007; Kessler et al., 2012; Wang et al., 2016). Furthermore, the major cause of 
death in people with COVID-19 is fatal pneumonia mediated in part by a hyper-
inflammatory response (Huang et al., 2020). Current expert opinions hypothesize 
that use of non-invasive vagus nerve stimulation may be a potential treatment 
strategy to mitigate the hyper-inflammatory syndrome in COVID-19 (Andersson et 
al., 2020; Staats et al., 2020). Therefore, the identification of novel therapeutic 
strategies, such as activators of the cholinergic anti-inflammatory pathway (e.g. 
GAT107, GTS-21, and vagus nerve stimulation), that restore host innate immune 
function to diminish the adverse effects of pneumonia are critically needed.  
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5.3. GAT107 Significantly Attenuates impaired Macrophage Innate 
Immune Functions produced by hyperoxia through mitigating the 
oxidation of F-Actin 
Our results indicated that GAT107 significantly attenuated the hyperoxia-induced 
impairment of macrophage phagocytic function in cultured macrophages and 
primary BMDMs (Figure 3). Previously, we and others have reported that prolonged 
exposure to hyperoxia compromises macrophage phagocytic function (Morrow et al., 
2007; Patel et al., 2013; Sitapara et al., 2014; Wang et al., 2015). Moreover, the partial-
α7nAChR agonist, GTS-21 (5-50µM), has been shown to restore the impaired 
phagocytic function produced by hyperoxia, which was due, in part, to a decrease in 
HMGB1 release from macrophages (Sitapara et al., 2014). The GTS-21-mediated 
decrease in airway HMGB1 also improved bacterial clearance in the airways of mice 
challenged with Pseudomonas aeruginosa (Sitapara et al., 2014). Similar to our 
bacterial clearance results (Figure 2), GTS-21, at 25-50 µM (Sitapara et al., 2014), and 
GAT107, at 3.3 µM, had similar efficacy in significantly attenuating hyperoxia-induced 
phagocytic dysfunction of cultured macrophages, which as previously discussed, may 
be due to the ago-PAM properties of GAT107 which produces greater efficacy than 
the partial-agonism of α7nAChR by GTS-21. In addition, the direct stimulation of the 
vagus nerve has been previously shown increase the basal and sepsis challenged 
phagocytic activity of resident liver macrophages (Fonseca et al., 2019), which 
suggests that activation of macrophages α7nAChR may play a critical role in 
modulating intracellular pathways that mediate phagocytic activity.  
Activation of neutrophil α7nAChRs with the direct agonist, nicotine, has been 
demonstrated to decrease the polymerization of F-actin (Huston et al., 2009). 
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Furthermore, macrophage phagocytic function is dependent upon the rapid 
polymerization of F-actin filaments for migration and phagocytosis of bacteria and to 
efferocytose apoptotic neutrophils (Capasso et al., 2016; Morrow et al., 2007; O’Reilly 
et al., 2003; Svitkina, 2018). However, previously, our lab and others have shown that 
the prolonged exposure to hyperoxia alone and in addition to PA infection, oxidizes 
actin filaments, resulting in dysfunctional actin polymerization (Morrow et al., 2007; 
O’Reilly et al., 2003). Antioxidants, such as procysteine and exogenous superoxide 
dismutase (SOD), protect against hyperoxia-induced disorganization of the actin 
cytoskeleton and attenuate phagocytic dysfunction (Morrow et al., 2007). As 
demonstrated in Figure 4, GAT107 significantly ameliorated hyperoxia-induced actin 
fiber disorganization by reducing the magnitude of protein oxidation. Protein 
oxidation of F-actin filaments may be due to macrophage activation, which increases 
superoxide production during the oxidative or respiratory burst response (Park, 
2003). The respiratory burst response involves the assembly of NADPH oxidase 
enzymes that generate large amounts of superoxide, which kill the ingested 
pathogens (Park, 2003). However, macrophages exposed to hyperoxia for prolonged 
periods of time have significantly increased intracellular levels of superoxide 
(Freeman et al., 1982; O’Donovan and Fernandes, 2000; Pagano and Barazzone-
Argiroffo, 2003). Consequently, hyperoxia exposure, in addition to activating 
respiratory bursts, may produce excessive oxidative stress, where high levels of ROS 
can induce the post-translational oxidation modifications of proteins such as actin 
(Chia et al., 2019; Rudyk and Eaton, 2014; van der Vliet et al., 2018). In addition, 
hyperoxia-compromised macrophages have compromised bactericidal functions to 
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kill ingested PA, which may be partly due to actin disorganization and subsequent 
dysfunction to assemble bactericidal enzymes or phagolysosomes (Gore et al., 2020). 
Overall, our results suggest that the efficacy of GAT107 to attenuate hyperoxia-
compromised macrophage function may be due, in part, to it decreasing the oxidation 
of actin filaments. 
5.4. GAT107 Ameliorates Oxidative Stress and Restores Antioxidant 
Functions  
Next, we sought to evaluate whether protein oxidation in macrophages indicated the 
possible presence of an oxidative-stress response in the lungs of hyperoxia-
compromised mice with PA lung infection. As demonstrated in Figure 5, 
administration of GAT107 to mice decreases hyperoxia-induced increases in ORP by 
increasing the total antioxidant potential in the lung tissue homogenate. In a 645-
person enrolled clinical trial for traumatic brain injury, a 20 mV increase in plasma 
ORP levels was correlated with a 4-fold increase in mortality rates (Rael et al., 2009). 
Conversely, a 1 unit increase in the inverse 1/cORP (antioxidant potential) was 
correlated with 5-fold increase in mortality rates (Rael et al., 2009). Recently, we have 
reported that in mice subjected to 72 h of hyperoxia, there was a significant increase 
in lung lavage fluid ORP levels (Patel et al., 2020). Furthermore, 24 h of hyperoxia 
exposure induces a significant increase in cultured macrophage lysate ORP levels 
(Patel et al., 2016). Moreover, in both of the aforementioned studies, ascorbic acid 
(50mg/kg i.p. or 1000 µM in cell culture) significantly decreased the hyperoxia-
induced increases in mouse lung lavage fluid and cultured macrophage lysate ORP 
levels and significantly improved animal mortality rates after challenge with PA lung 
infection (Patel et al., 2020, 2016).  
54 
 
As shown in Figure 6, similar to the results obtained in total lung homogenate, the 
prolonged exposure to hyperoxia increased total ROS levels in macrophages and also 
significantly decreased the antioxidant activity of SOD1. Our results demonstrated 
that treatment with GAT107 attenuated the hyperoxia-induced increase in 
macrophage ROS levels and also restored SOD1 activity. We hypothesize that 
GAT107’s activation of the α7nAChR may be restoring hyperoxia-compromised SOD1 
activity by transcriptional upregulation and expression of SOD1 or by altering 
inhibitory post-translational regulatory modifications of SOD1 (Dinesh and Rasool, 
2017). As discussed previously, prolonged exposure to hyperoxia and the activation 
of macrophages induces the production of high levels of ROS such as superoxide 
directly in the cytosol or indirectly by ROS leakage from the mitochondria into the 
cytosol. Normally, the major antioxidant in the cytoplasm that removes superoxide is 
SOD1 (Fukai and Ushio-Fukai, 2011; M. Fetherolf et al., 2017). Decreased SOD1 
activity during hyperoxic conditions may therefore further affect the production and 
levels of cytoplasm superoxide. As such, the cytoplasmic abrogation of elevated ROS 
levels along with a compromised antioxidant defense system may then further 
participate and contribute to the oxidation of macromolecules such as F-actin. 
Although the exact amino acid residues in actin that are oxidized by hyperoxia remain 
to be determined, biochemical analysis and computational modeling suggest that 
NOX-mediated superoxide production and oxidation of actin F-actin filaments may 
occur at Cys10, 217, 257, 285, and 374 (Wilson et al., 2016).  
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5.5. GAT107 Activates Nrf2 and Upregulates HO-1 
The GAT107-mediated restoration of the hyperoxia-induced redox imbalances may 
be due to its activation of the master antioxidant pathway, Nrf2 (Figure 7). Recently, 
we and others have shown that the activation of the Nrf2 pathway in macrophages in 
vitro and ex vivo in mice significantly increases innate immune functions and 
decreases lung injury (Cho et al., 2002; Patel et al., 2020; Reddy et al., 2009). The 
activation of α7nAChR by acetylcholine or GTS-21 results in downstream Nrf2 
activation and the transcriptional upregulation of the genes that produce 
antioxidants such as glutathione (Hoover, 2017; Pagano and Barazzone-Argiroffo, 
2003; Patel et al., 2017; Tsoyi et al., 2011; Zhang et al., 2019).  
Heme oxygenase-1 (HO-1) is a Nrf2-regulated antioxidant that has been shown to 
decrease oxidative-induced lung injury (Cho et al., 2002; Choi and Alam, 1996; Reddy 
et al., 2009; Ryter and Choi, 2016). Under hyperoxic conditions, HO-1 null 
cardiomyocytes exhibit mitochondrial damage and decreased density, which may be 
due to heme toxicity (Suliman et al., 2017). Furthermore, hyperoxia exposure 
increases the number of hemoproteins and free reactive iron in lung tissues of mice 
(Dennery et al., 1998). It is likely that many of the free iron or heme groups found in 
these hyperoxia-compromised subjects are originated from cytochromes, 
cyclooxygenases, and other heme containing proteins found in the mitochondria 
(Soares and Hamza, 2016). The accumulation of free heme in macrophages results in 
heme-induced cell death characterized by damage to proteins, DNA, and lipid 
peroxidation (Vijayan et al., 2018) 
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 HO-1 is the rate-limiting enzyme in heme metabolism, which results in the 
production of approximately 86% of all carbon monoxide (Ryter and Choi, 2013; 
Slebos et al., 2003). Furthermore, carbon monoxide produced by HO-1 has been 
shown neutralize free iron and also activate anti-inflammatory pathways by 
downregulating pro-inflammatory cytokine production (Slebos et al., 2003; Soares 
and Hamza, 2016). Treatment with exogenous carbon monoxide protects against 
hyperoxia-induced endothelial cell apoptosis via exerting antioxidant functions and 
promoting the interaction of HO-1 with the pro-apoptotic factor, Bax (Wang et al., 
2007). Interestingly, in hyperoxic-rat models, there is minimal transcriptional 
upregulation of HO-1 mRNA at 48h, and from 48h to 64h of continuous hyperoxia 
exposure, there is a steady-state increase in HO-1 mRNA (Choi and Alam, 1996; Lee 
et al., 1996). However, during this time, there is a substantial increase in rat mortality 
rates after 60 and 72h of continuous hyperoxia (Choi and Alam, 1996; Clerch and 
Massaro, 1993; Lee et al., 1996). In rats that received an HO-1 gene transfer and 
exposed to hyperoxia, there were significantly improved mortality rates, lung injury, 
and increased lung HO-1 mRNA and protein levels (Otterbein et al., 1999). In HO-1-
deficient mice with sepsis, there was a decrease in the bacterial removal by 
macrophages, and this was attenuated by pretreating animals with carbon monoxide-
releasing molecules (Chung et al., 2008). Conversely, it has also been shown in mice 
with the disrupted or inhibited expression of HO-1 and exposed to hyperoxia, that 
these mice are more protected from inflammatory lung injury and have decreased 
levels of total reactive iron in the lung (Dennery et al., 2003). Thus, the exact role that 
HO-1 plays in the lungs of mice and macrophages exposed to hyperoxia is not fully 
57 
 
understood, but the early induction of HO-1 by GAT107 may serve as a critical 
antioxidant involved in ameliorating hyperoxia-induced lung injury and improving 
the innate immune response in the bacterial clearance ability by macrophages. 
5.6. Hyperoxia Disrupts Mitochondrial Membrane Integrity  
As demonstrated in Figure 8A, mitochondrial membrane hyperpolarization occurs in 
macrophages exposed to 24 h of hyperoxia. Indeed, the hyperpolarization of 
mitochondrial membrane potential in T cells precedes terminal mitochondrial 
damage, resulting in cell death (Perl et al., 2004). Furthermore, mitochondrial 
hyperpolarization may indicate a dysregulation of oxidative phosphorylation, which 
increases ROS generation and the subsequent loss of ATP production (Chen et al., 
2017; Pak et al., 2013, p. 20). The buildup of protons in the intermembrane space due 
to the inhibition of F0F1-ATPase proton motor functions can cause an electrochemical 
gradient shift resulting in a hyperpolarized mitochondrial membrane potential and 
the uncoupling of oxidative phosphorylation (Perl et al., 2004). As shown in Figure 8, 
hyperoxia-induced about a 41% increase in mitochondrial membrane polarization, 
and it has been reported that an increase of 28-32% mitochondrial membrane 
potential causes ETC uncoupling, disrupted ATP generation, and significant ROS 
generation (Perl et al., 2004; Skulachev, 1999). There are at least ten known sites of 
physiological ROS generation in the mitochondria (Lin and Beal, 2006; Orrenius et al., 
2007; Starkov, 2008). However, it has been reported that in the presence of high 
levels of oxygen, the mitochondrial flavoprotein quinone oxidoreductase may be the 
sole cause of the increase in ROS levels (Hoffman and Brookes, 2009). In mice exposed 
to 72 h of hyperoxia, there is a significant inhibition of complex I activity (a known 
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cause of ROS generation) and decreased ATP production in isolated pulmonary 
mitochondria (Ratner et al., 2009). As demonstrated in this study (Figure 8A), 
GAT107 was able to significantly attenuate hyperoxia-induced macrophage 
mitochondrial hyperpolarization. Therefore, through normalizing the mitochondrial 
membrane potential, GAT107 is capable of mediating the maintenance of 
mitochondrial integrity and thus help establish conditions that resemble normal 
mitochondrial function.  
5.7. GAT107 significantly attenuates the hyperoxia-induced decrease in 
MnSOD activity 
Under normal physiological conditions, MnSOD catalyzes the dismutation reaction of 
mitochondrial superoxide into hydrogen peroxide at a rate of 2 x 109M-1s-1, which can 
be then quickly converted by catalase in water (Candas and Li, 2014; Ozden et al., 
2011; Wang et al., 2018). However, as shown in Figure 9C, 24 h of hyperoxia exposure 
significantly decreased MnSOD activity. Other investigations have reported that the 
intermittent exposure of macrophages to hyperoxia significantly decreases MnSOD 
function at 7 days, but interestingly, after 3-weeks, MnSOD function is significantly 
increased (Kokubo et al., 2010). Conversely, guinea pigs exposed to hyperoxia for 3 
days, alveolar macrophage MnSOD function was significantly increased (Aerts et al., 
1995). However, in cultured macrophages overexpressing MnSOD or incubated with 
exogenous SOD, macrophages had significantly greater phagocytic capacity for PA 
after exposure to 24h of hyperoxia (Arita et al., 2007; Morrow et al., 2007).  
In our study, GAT107 restored mitochondrial function as indicated by the 
normalization of mitochondrial membrane potential (Figure 8A). In addition, GAT107 
also normalized mitochondrial superoxide levels (Figure 8B). The GAT107 - mediated 
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normalization of mitochondrial superoxide levels were also associated with the 
attenuation of hyperoxia-compromised MnSOD function (Figure 9B), suggesting that 
the generation of excessive mitochondrial superoxide may result from MnSOD 
dysfunction. Moreover, GAT107’s restorative effect of MnSOD function was not 
dependent on the overall protein levels of MnSOD (Figure 9A). Interestingly, in 
cultured macrophages exposed to 3-weeks of intermittent hyperoxia, macrophages 
survived only if they express significantly higher levels of MnSOD activity (Kokubo et 
al., 2010). Therefore, since GAT107 did not significantly alter the total protein levels 
of MnSOD, it suggests that MnSOD activity is not being modulated MnSOD protein 
levels. Thus, it is possible that GAT107 may be increasing MnSOD activity by post-
translational modifications (Ho et al., 1996).  
Indeed, it has been shown that post-translational modifications of MnSOD alters its 
enzymatic function (Candas and Li, 2014; Demicheli et al., 2018; Dikalova et al., 2017; 
Kim et al., 2017; Patil et al., 2013; Yamakura and Kawasaki, 2010). The 
glutathionylation of proteins has been reported to have a protective role against 
irreversible oxidative modifications (e.g. sulfonic acid) of reactive cysteine residues 
(Hurd et al., 2005; Janssen-Heininger et al., 2013). As shown in Figure 10, hyperoxia 
induces the glutathionylation of MnSOD and is significantly ameliorated by GAT107 
(3.3 µM) treatment. Furthermore, the increase in MnSOD glutathionylation was 
significantly correlated with decreased MnSOD activity (Figure 10), demonstrating 
that glutathionylation of MnSOD modulates its enzymatic activity. Previously, it has 
been reported that under oxidative stress conditions, non-mitochondrial SOD1 is 
glutathionylated at Cys111 and FeSOD is glutathionylation at Cys57 (Candas and Li, 
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2014). Currently, it remains to be determined how GAT107 decreases the 
glutathionylation of MnSOD. We postulate that GAT107 may be reducing MnSOD 
glutathionylation through pathways that augment the mitochondrial antioxidant 
capacity, thereby decreasing the oxidative burden on MnSOD by the GAT107-induced 
activation of the Nrf2/HO-1 pathway. It may be likely that the upregulation of HO-1 
can cause preferential mitochondrial translocation. In human lung epithelial cells 
exposed to particulate matter 2.5 µm (PM2.5) collected from air pollution, it was 
determined that there was a significant increase in preferential transposition of HO-
1 into the mitochondria, which may play a protective role in PM2.5 induced necrosis 
(Zhou et al., 2017). It has been previously reported that the activation of α7nAChR by 
acetylcholine or GTS-21 results in downstream Nrf2 activation and the 
transcriptional upregulation of antioxidants such as glutathione (Báez-Pagán et al., 
2015; Hoover, 2017; Patel et al., 2017; Tsoyi et al., 2011; Zhang et al., 2019). It is likely 
that under oxidative stress conditions, both non-enzymatically and enzymatically 
catalyzed glutathionylation reactions occur in the mitochondria since the 
mitochondrial concentration of glutathione are approximately 5-10 mM (Hurd et al., 
2005). Also, the de-glutathionylation of proteins may be facilitated by sulfiredoxins, 
glutaredoxin 2 (Grx2), and thioredoxin (Trx2) (Chia et al., 2019; Findlay et al., 2006; 
Janssen-Heininger et al., 2013). Thus, GAT107 could influence the de-
glutathionylation of proteins by acting on one of these de-glutathionylating enzymes, 
although this remains to be determined. It may be likely that in hyperoxia-induced 
lung injury that there is dysregulation of proteins that maintain the glutathionylation 
profile of proteins since dysregulation of glutathionylation has been linked to lung 
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diseases such as idiopathic pulmonary fibrosis, asthma, and chronic obstructive 





As shown in Figure 11, the α7nAChR type 2 ago-PAM, GAT107, attenuates hyperoxia-
induced innate immune dysfunction of mice with PA lung infection. GAT107 restored 
bacterial clearance functions of mice, in part, by mitigating hyperoxia-induced 
macrophage phagocytic dysfunction. Hyperoxia exposure also oxidized F-actin 
filaments in macrophages, which was reduced in cells incubated with GAT107. In 
mice exposed to hyperoxia with PA lung infection, there was a significant increase in 
lung oxidative stress and reduced antioxidant potentials that were attenuated by 
GAT107 administration. Indeed, in macrophages, GAT107 decreased the significant 
increase in intracellular ROS levels and loss of SOD1 antioxidant function produced 
by hyperoxia. GAT107 appeared to mediate the aforementioned effects of hyperoxia 
by activating Nrf2 and upregulating HO-1 expression. GAT107 attenuated the 
hyperoxia-compromised mitochondrial function and enhanced MnSOD function. 
Moreover, hyperoxia-induces MnSOD glutathionylation, which correlates 
significantly to decreased MnSOD function. Importantly, GAT107 reduces the amount 
of hyperoxia-induced MnSOD glutathionylation. Therefore, GAT107 restores 
mitochondrial function through modulating the glutathionylation status of MnSOD, 
which may participate in regulating oxidative stress-induced macrophage 
dysfunction. 
Other studies have indicated that the inhibition of α7nAChR with antagonists 
(methyllycaconitine and α-bungarotoxin), only partially reduces GTS-21’s efficacy to 
inhibit LPS-induced secretion of IL-6 and TNFα (Garg and Loring, 2019). GTS-21 also 
partially ameliorates LPS-induced secretion of both IL6 and TNFα from cultured 
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macrophages where the a7nAChR gene was knocked out (Garg and Loring, 2019). In 
our study, we did not determine whether the efficacy of GAT107 was due to it 
selective activation of the α7nAChR. Thus, is it possible that GAT107 may interact 
with non-α7nAChR targets and future studies will be required to identify these 
targets. Therefore, regardless of GAT107’s mechanism of action, our results suggest 
that GAT107 may be a potential therapeutic candidate for the prevention and/or 
treatment of subjects with oxygen therapy - induced compromised immunity, 




7. FUTURE DIRECTIONS 
7.1. Exploring the efficacy of GAT107 on modulating hyperoxia-
compromised mice and macrophages  
A potential direction for future investigation is to further delineate the mechanisms 
underlying hyperoxia-induced mitochondrial dysfunction in macrophages. 
Connecting these features with ETC function, ATP production, and the role of redox 
imbalance via glutathionylation mechanisms is needed. Moreover, it is well 
established that lung protein glutathionylation plays a critical pathological role in the 
pathogenesis of lung diseases like asthma and idiopathic pulmonary fibrosis (Chia et 
al., 2019; Janssen-Heininger et al., 2013), however, it would be interesting to explore 
the role lung protein glutathionylation plays in hyperoxia-induced acute lung injury 
and macrophage dysfunction. Since this current study established that GAT107 
induces an antioxidant response in mouse lung tissue and in macrophages, it would 
be interesting to explore what enzymes, such as glutathione S-transferase, 
glutaredoxin, thioredoxin, and peroxiredoxins, are involved in the glutathionylation 
or de-glutathionylation process of MnSOD and possible other proteins.  
In these results, our lab has demonstrated that GAT107 can improve the bacterial 
clearance functions of mice with PA lung infection through alleviating hyperoxia-
induced macrophage dysfunction (Figure 11). Recently, our lab has shown that GTS-
21 can alleviate inflammatory lung injury in mice subjected to the prolonged 
exposure to hyperoxia (Sitapara et al., 2020). Increased lengths of hyperoxia 
exposure along with hyperoxia-induced inflammatory lung injury in combination 
with PA lung infection-induced lung injury contribute to poor prognosis’ and higher 
mortality rates in ventilated-associated pneumonia patients (Bassi et al., 2014; 
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Oliveira et al., 2014; Rello, 2005; Spalding et al., 2017; M. Wang et al., 2019). Thus, 
extending this study to determine if GAT107 ameliorates inflammatory lung injury is 
needed in order to fully ascertain the efficacy of GAT107 on improving survival rates 
in hyperoxia-compromised mice with PA lung infection. Indeed, inflammatory lung 
injury in hyperoxia-compromised subjects with and without PA lung infection can be 
attenuated via using neutralizing anti-HMGB1 antibodies to target extracellular 
HMGB1 in the airways of mice (Entezari et al., 2014; Patel et al., 2013). The 
accumulation of extracellular HMGB1 in the airways of mice is an important mediator 
of hyperoxia’s role in compromising alveolar macrophage functions. In addition, 
HMGB1’s unique pathological role may be both temporal and concentration 
dependent, yielding a striking and currently under explored pleiotropic role in the 
lung. Treatment with HMGB1 can directly cause macrophage dysfunction (Entezari et 
al., 2012) and can stimulate the endocytosis of HMGB1 into macrophages and both 
cause and contribute to a hyper-inflammatory response. Extracellular HMGB1 can 
augment pro-inflammatory responses of bacterial and viral pathogens (pathogen 
associated molecular patterns (PAMPS)) via the formation of HMGB1-PAMP 
conjugates (Andersson et al., 2020; Lu et al., 2014). These HMGB1-PAMP conjugates 
can then be endocytosed by macrophages and synergize the pro-inflammatory 
response, which may be a significant contributing factor underlying the cytokine-
storm syndrome in COVID-19 (Andersson et al., 2020). Thus, it would be also 
beneficial to explore the role of GAT107 in ameliorating the secretion and 
extracellular accumulation of HMGB1 from macrophages in the context of treating 
inflammatory lung injury in oxygen-therapy treated patients, especially in COVID-19.  
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7.2. Can we use α7nAChR activators like GAT107 for the treatment of 
COVID-19? 
The coronavirus disease of 2019 (COVID-19) caused by SARS-CoV2 is a complex 
disease that has profound effects on the lung, central nervous system, circulatory 
system’s clotting mechanisms, cardiac tissue, and the gastrointestinal system 
(Farsalinos et al., 2020b, 2020a; Rothan and Byrareddy, 2020). As of the writing of 
this dissertation, the coronavirus pandemic has approximately 13,500,000 confirmed 
cases and 9350,000 confirmed deaths worldwide. Current CDC estimates have 
determined that 81% of patients with COVID-19 experience mild to moderate 
symptoms including shortness of breath and mild forms of pneumonia (To et al., 
2020). In addition, between 14 and 5% of patients experience severe to critically 
severe COVID-19 symptoms, respectively, which includes dyspnea, hypoxia, up to 
respiratory failure and multiple organ failure (To et al., 2020). In the United States, 
approximately 19% of all COVID-19 patients require hospitalization, of which, 6% are 
admitted to Intensive Care Units (ICU) (Li et al., 2020). Although there is a wide range 
of symptoms for COVID-19 patients, around 3 to 17% of all COVID-19 patients are 
diagnosed with one of the hallmarks of severe COVID-19 (N. Chen et al., 2020; Guan 
et al., 2020; Huang et al., 2020; Wang et al., 2020; Wu et al., 2020; Yang et al., 2020), 
which is acute respiratory distress syndrome (ARDS) that results in the need for 
patients to be mechanically ventilated as a life-saving intervention (Coperchini et al., 
2020). Ultimately, of the critically severe COVID-19 patients whom are admitted into 
ICUs, there is an approximate 39 to 72% mortality rate (Huang et al., 2020; Wu et al., 
2020; Yang et al., 2020). 
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Early on, the clinical observations that studied COVID-19 disease progression 
determined that around 14% of all patients suffer from peripheral bilateral ground 
glass opacities by CT scan, which indicated that these patients were suffering with a 
partial airway filling of fluids and pulmonary wall thickening and also 75% of all 
patients have pneumonia (N. Chen et al., 2020). Moreover, this hallmark symptom of 
lung inflammation in severe COVID-19 has recently been hypothesized to be 
condition known as the “cytokine-storm”, whereby the presence of excessive levels 
of pro-inflammatory cytokines exacerbate lung injury and promote multiple organ 
failure (Coperchini et al., 2020).  
In this brief communication, the detailed mechanisms for SARS-CoV2 induced hyper-
cytokemia are outside of the scope of this article, but we recommend reading 
Coperchini et al. (2020) for those concepts. Classically, the cytokine-storm syndrome 
is mediated in part by a hyperactive response of immunomodulatory molecules that 
results in high plasma levels of TNF-a, and interleukins including IL-1b, IL-8, and IL-
6 (Lee et al., 2014). In the context of COVID-19, 5 separate study cohorts have 
reported that plasma levels of IL-6 range from 7 to 64 ng/mL in patients with severe 
disease phenotypes, which has previously been thought to be a major mediator of 
acute lung injury and ARDS (Sinha et al., 2020). However, as reported in 3 large cohort 
lung study groups (ALVEOLI, FACT, and SAILSS), non-COVID19 patients with 
diagnosed ARDS have plasma levels of IL-6 that range from 130 to 443 ng/mL in 
patients with a hypoinflammatory response and up to a 578 to 1618 ng/mL in 
patients with a hyperinflammatory response (Sinha et al., 2020). Although this 
disparity in the role in IL-6-mediated ARDS may be evident within patient plasma 
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samples compared between COVID-19 and large cohort ARDS studies exists, several 
therapeutics have been developed to target IL-6 as a COVID-19 treatment strategy. 
The monoclonal antibodies against Ll-6, tocilizumab and sarilumab, are being used 
currently to treat the cytokine release syndrome for COVID-19 (clinical trials 
NCT04306705 and NCT04322773). Currently, due to the expedited clinical trial 
pipeline given to the development of these IL-6 targeted therapies and low clinical 
trial populations, the US FDA has still been unable to approve use of any IL-6 inhibitor 
for the treatment of COVID-19 (“Immune-Based Therapy | Coronavirus Disease 
COVID-19,” n.d.; Mehta et al., 2020). Internationally, clinicians are hopeful yet 
concerned about IL-6 therapies, due to the presence of several negative side effects. 
For instance, IL-6 inhibitors are noted for having the ability to increase the risk and 
rate of opportunistic infections (Calabrese et al., 2020). Moreover, clinically relevant 
models that simulate the use of oxygen therapy for prolonged periods of time, such 
as in those individuals receiving treatment for COVID-19, that the overexpression of 
IL-6 is protective against oxygen-induced lung injury in mice (Ward et al., 2000). 
Thus, it is still unclear what definitive role IL-6 is playing in COVID-19, which has been 
a catalyst for other investigations to continue searching for other possible therapeutic 
targets.  
Recent epidemiological evidence shows that based on Chinese clinical trials, that 
smokers (N = 159 people) are statistically less likely to be hospitalized due to COVID-
19 (total N = 1623 people) (Gonzalez-Rubio et al., 2020; Polosa and Caci, 2020). 
Moreover, non-peer reviewed clinical observations in France found that patients that 
are current smokers (<5% of all COVID-19 patients) are protected against SARS-CoV2 
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pathophysiology (Changeux et al., 2020). Although these studies and others have 
been steeped in hotly contested debate, the general conclusions definitively state that 
smoking tobacco is incredibly harmful, but perhaps the inhaled nicotine, with can be 
found in tobacco smoke, may have efficacious effects on ameliorating COVID-19 
symptom severity. Indeed, nicotine as an anti-inflammatory molecule has been long 
recognized as an activating molecule of the cholinergic anti-inflammatory pathway 
(Pavlov et al., 2003; Scott and Martin, 2006). 
Between the clinical data showing a possible link between COVID-19 disease severity 
and the exacerbated lung injury induced by SARS-CoV2 hyper-cytokemia (a.k.a. the 
cytokine-storm), COVID-19 has been postulated to be a disease of the cholinergic anti-
inflammatory pathway (Andersson et al., 2020; Farsalinos et al., 2020a; Gonzalez-
Rubio et al., 2020; Mazloom, 2020). The fundamental underpinning of this theory lies 
in the COVID-19-induced imbalance in control of cytokine secretion, which normally 
is maintained via vagus nerve mediated cholinergic signaling.  
The cholinergic anti-inflammatory operates by the afferent vagus nerve sensing the 
presence of pathogens, damage-associated molecular patterns, and 
cytokines/chemicals. The afferent vagus nerve then signals to the central nervous 
system, and then communicates via the efferent vagus nerve to effector organs. At 
least in the lung, neuroendocrine cells receive effect vagus nerve innervations that 
form the parasympathetic nervous system relay (Wu et al., 2014). Activation of these 
pulmonary neuroendocrine cells found in the distal airways induces the release of 
acetylcholine, which can modulate the local inflammatory environment by binding to 
and activating the α7 nicotinic acetylcholine receptor (α7nAChRs) on alveolar 
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macrophages (Borovikova et al., 2000; Pavlov et al., 2003; Wang et al., 2003; Wu et 
al., 2014).  
As previously mentioned, COVID-19 patients experiencing symptoms ranging from 
shortness of breath, hypoxemia, ARDS, and respiratory failure, receive some form of 
either non-invasive or invasive mechanical ventilation oxygen therapy. However, it is 
unclear whether the lung injury in COVID-19 patients is purely due to normal viral 
pathogenesis, patient induced lung injury (Fan et al., 2020), or exacerbated by the 
oxygen therapy itself. In clinically relevant laboratory models that simulate the use of 
oxygen therapy, the prolonged exposure to high concentrations of oxygen can directly 
cause injury to the lungs (Entezari et al., 2014; Patel et al., 2020; Ward et al., 2000). 
Moreover, these models of hyperoxia-induced inflammatory lung injury also can 
retain the cytokine-storm syndrome similar to what is observed in COVID-19 
patients. In subjects with hyperoxia-induced inflammatory lung injury, the systemic 
administration of a small molecule called GTS-21, activates the α7nAChR-mediated 
cholinergic anti-inflammatory, which results in attenuated lung injury in mice 
(Andersson et al., 2020; Sitapara et al., 2020).  
GTS-21 mediated the amelioration of inflammatory lung injury by significantly 
reducting both plasma and airway levels of the damage associated molecular pattern, 
high mobility group box-1 (HMGB1) (Sitapara et al., 2020). Importantly, increased 
plasma levels of HMGB1 have recently been shown to be significantly correlated with 
more severe clinical COVID19 outcomes that result in the increased ICU 
hospitalization and death rates (L. Chen et al., 2020). As such, use of therapeutics that 
activate the α7nAChR-mediated cholinergic anti-inflammatory pathway like nicotine 
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or GTS-21, that decrease the secretion of HMGB1 may be critical in preventing COVID-
19 patients from severe disease complications.  
HMGB1 as a target for treating COVID-19 has recently gained more attention. In other 
disease models, extracellular HMGB1 has been shown to form complexes with viral 
and bacterial pathogen, and damage associated molecules (Andersson et al., 2020; L. 
Chen et al., 2020). HMGB1 complexes are then endocytosed via RAGE receptors on 
innate immune cells, such as macrophages. Internalized HMGB1-complexes then can 
activate cytosolic receptors that activate inflammasome and cell death pathways 
(Andersson et al., 2020; Lu et al., 2014). It is hypothesized that HMGB1 can form 
complexes with SARS-CoV2 RNA fragments, which can then be up taken into innate 
immune cells to further exacerbate the host innate hyper-inflammatory response to 
SARS-CoV2 infection (Andersson et al., 2020). Moreover, activation of macrophage 
α7nAChR’s with small molecule agonists (acetylcholine and GTS-21), have been 
shown to inhibit the activation of inflammasomes via attenuating the endocytosis of 
HMGB1-LPS complexes into the cell (Lu et al., 2014; Yang et al., 2019).  
Recent epidemiological studies have demonstrated that men and women have similar 
prevalence rates for COVID-19, but however, men are statistically more susceptible 
to severe COVID-19 symptoms and higher mortality rates (Jin et al., 2020). In 
pulmonary arterial hypertension patients, men have higher mortality rates, which 
was found to be to an increased level of pulmonary vascular necrosis and an increased 
amount of HMGB1 released into the extracellular milieu (Rafikov et al., 2019; 
Zemskova et al., 2020). Therefore, HMGB1 may be a possible contributing mechanism 
to explain why men with COVID-19 have higher mortality rates than compared to 
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women. Therefore, activation of the cholinergic anti-inflammatory pathway with 
α7nAChR activators has 2 hypothetical main modes of protection against SARS-CoV2 
infection: 1) through the attenuation of SARS-CoV2 induced hyper-cytokemia, 
especially HMGB1, and by 2) inhibiting HMGB1-SARS-CoV2 RNA complexes that 
further exacerbate the hyper-inflammatory response. 
In addition, in silico-based investigations have discovered a potential interaction 
between the α7nAChR and the SARS-CoV2 glycoprotein spike protein (Farsalinos et 
al., 2020b). Indeed, the interaction between α7nAChR and the spike protein was 
within the same magnitude as alpha-bungarotoxin, the snake venom derived 
molecule that selectively antagonizes the α7nAChR (Farsalinos et al., 2020b). Thus, it 
was hypothesized that this interaction may play a critical role in disrupting the 
cholinergic anti-inflammatory system for COVID-19 patients, and it may explain of 
why severe COVID-19 patients present severe ARDS and lung inflammation.  
Currently, there is conflicting data on whether nicotine’s role in modulating the 
expression of angiotensin 2 receptor (ACE2) is protective or harmful in SARS-CoV2 
infection (C et al., 2020; Simons et al., 2020; Tindle et al., 2020). Depending on the 
organ and cell-type, nicotine has pleiotropic effects on ACE2 receptor expression 
(Leung et al., 2020; Tindle et al., 2020). The ACE2 receptor is the primary entry-point 
by which SARS-CoV2 infiltrates the cell. However, in silico molecular docking studies 
have revealed that nicotine may bind to ACE2 and competitively inhibit the ACE2-
SARS-CoV2 complex (C et al., 2020). Therefore, although nicotine may have a 
potential role in mediating SARS-CoV2 cell invasion, nicotine has a well-established 
potent anti-inflammatory property that may be useful in the treatment or prevention 
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of COVID-19 associated ARDS. Nicotine, under the strict supervision and guidance of 
a physician, may then therefore be a potential therapeutic strategy in conjunction 
with palliative care, anti-virals, antibiotics, and antibodies for COVID-19, if used 
under heavily controlled conditions.  
Given the wide availability commercially for nicotine containing products, their 
affordable manufacturing cost, and a range of delivery routes that can be tailored to 
meet individual patient needs, nicotine has then been thought to be a likely potential 
treatment in conjunction with anti-virals, antibodies, and antibiotics for the 
treatment of COVID-19. As a disclaimer, the use of tobacco products is known to cause 
cancer and increases the susceptibility to infections, so only under the strict 
supervision of a physician-guided treatment strategy should nicotine ever be 






Aerts, C., Wallaert, B., Gosset, P., Voisin, C., 1995. Relationship between oxygen-
induced alveolar macrophage injury and cell antioxidant defence. Journal of 
Applied Toxicology 15, 53–58. https://doi.org/10.1002/jat.2550150112 
Allard, B., Panariti, A., Martin, J.G., 2018. Alveolar Macrophages in the Resolution of 
Inflammation, Tissue Repair, and Tolerance to Infection. Front Immunol 9. 
https://doi.org/10.3389/fimmu.2018.01777 
Andersson, U., Ottestad, W., Tracey, K.J., 2020. Extracellular HMGB1: a therapeutic 
target in severe pulmonary inflammation including COVID-19? Molecular 
Medicine 26, 42. https://doi.org/10.1186/s10020-020-00172-4 
Arita, Y., Kazzaz, J.A., Joseph, A., Koo, H., Li, Y., Davis, J.M., 2007. Antioxidants 
improve antibacterial function in hyperoxia-exposed macrophages. Free 
Radic. Biol. Med. 42, 1517–1523. 
https://doi.org/10.1016/j.freeradbiomed.2007.02.003 
Báez-Pagán, C.A., Delgado-Vélez, M., Lasalde-Dominicci, J.A., 2015. Activation of the 
Macrophage α7 Nicotinic Acetylcholine Receptor and Control of 
Inflammation. J Neuroimmune Pharmacol 10, 468–476. 
https://doi.org/10.1007/s11481-015-9601-5 
Bagdas, D., Wilkerson, J.L., Kulkarni, A., Toma, W., AlSharari, S., Gul, Z., Lichtman, 
A.H., Papke, R.L., Thakur, G.A., Damaj, M.I., 2016. The α7 nicotinic receptor 
dual allosteric agonist and positive allosteric modulator GAT107 reverses 
nociception in mouse models of inflammatory and neuropathic pain. Br J 
Pharmacol 173, 2506–2520. https://doi.org/10.1111/bph.13528 
Baleeiro, C.E., Wilcoxen, S.E., Morris, S.B., Standiford, T.J., Paine 3rd, R., 2003. 
Sublethal hyperoxia impairs pulmonary innate immunity. Journal of 
immunology (Baltimore, Md.: 1950) 171, 955–963. 
Barbier, F., Andremont, A., Wolff, M., Bouadma, L., 2013. Hospital-acquired 
pneumonia and ventilator-associated pneumonia: recent advances in 
epidemiology and management. Current Opinion in Pulmonary Medicine 19, 
216–228. https://doi.org/10.1097/MCP.0b013e32835f27be 
Bassetti, M., Vena, A., Croxatto, A., Righi, E., Guery, B., 2018. How to manage 
Pseudomonas aeruginosa infections. Drugs Context 7. 
https://doi.org/10.7573/dic.212527 
Bassi, G.L., Ferrer, M., Marti, J.D., Comaru, T., Torres, A., 2014. Ventilator-associated 
pneumonia. Semin Respir Crit Care Med 35, 469–481. 
https://doi.org/10.1055/s-0034-1384752 
Beauchamp, C., Fridovich, I., 1971. Superoxide dismutase: improved assays and an 
assay applicable to acrylamide gels. Anal. Biochem. 44, 276–287. 
https://doi.org/10.1016/0003-2697(71)90370-8 
Bhatti, J.S., Bhatti, G.K., Reddy, P.H., 2017. Mitochondrial dysfunction and oxidative 
stress in metabolic disorders — A step towards mitochondria based 
therapeutic strategies. Biochimica et Biophysica Acta (BBA) - Molecular Basis 
of Disease, Oxidative Stress and Mitochondrial Quality in Diabetes/Obesity 
75 
 
and Critical Illness Spectrum of Diseases 1863, 1066–1077. 
https://doi.org/10.1016/j.bbadis.2016.11.010 
Birben, E., Sahiner, U.M., Sackesen, C., Erzurum, S., Kalayci, O., 2012. Oxidative Stress 
and Antioxidant Defense. World Allergy Organ J 5, 9–19. 
https://doi.org/10.1097/WOX.0b013e3182439613 
Borovikova, L.V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G.I., Watkins, L.R., Wang, 
H., Abumrad, N., Eaton, J.W., Tracey, K.J., 2000. Vagus nerve stimulation 
attenuates the systemic inflammatory response to endotoxin. Nature 405, 
458–462. https://doi.org/10.1038/35013070 
Borregaard, N., Herlin, T., 1982. Energy Metabolism of Human Neutrophils during 
Phagocytosis. J Clin Invest 70, 550–557. 
Branson, R.D., 2018. Oxygen Therapy in COPD. Respir Care 63, 734–748. 
https://doi.org/10.4187/respcare.06312 
Burton, G.J., Jauniaux, E., 2011. Oxidative stress. Best Pract Res Clin Obstet Gynaecol 
25, 287–299. https://doi.org/10.1016/j.bpobgyn.2010.10.016 
Byrne, A.J., Mathie, S.A., Gregory, L.G., Lloyd, C.M., 2015. Pulmonary macrophages: 
key players in the innate defence of the airways. Thorax 70, 1189–1196. 
https://doi.org/10.1136/thoraxjnl-2015-207020 
C, S.K., Kumar, S.A., Wei, H., 2020. A computational insight of the improved nicotine 
binding with ACE2-SARS-CoV-2 complex with its clinical impact. 
arXiv:2004.14943 [q-bio]. 
Calabrese, C., Rajendram, P., Sacha, G., Calabrese, L., 2020. Practical aspects of 
targeting IL-6 in COVID-19 disease. CCJM ccjom;ccjm.87a.ccc018v2. 
https://doi.org/10.3949/ccjm.87a.ccc018 
Candas, D., Li, J.J., 2014. MnSOD in oxidative stress response-potential regulation via 
mitochondrial protein influx. Antioxid. Redox Signal. 20, 1599–1617. 
https://doi.org/10.1089/ars.2013.5305 
Capasso, D., Pepe, M.V., Rossello, J., Lepanto, P., Arias, P., Salzman, V., Kierbel, A., 
2016. Elimination of Pseudomonas aeruginosa through Efferocytosis upon 
Binding to Apoptotic Cells. PLoS Pathog 12, e1006068. 
https://doi.org/10.1371/journal.ppat.1006068 
Chang, E.H., Chavan, S.S., Pavlov, V.A., 2019. Cholinergic Control of Inflammation, 
Metabolic Dysfunction, and Cognitive Impairment in Obesity-Associated 
Disorders: Mechanisms and Novel Therapeutic Opportunities. Front. 
Neurosci. 13. https://doi.org/10.3389/fnins.2019.00263 
Changeux, J.-P., Amoura, Z., Rey, F., Miyara, M., 2020. A nicotinic hypothesis for 
Covid-19 with preventive and therapeutic implications. Qeios. 
https://doi.org/10.32388/FXGQSB 
Chastre, J., Fagon, J.Y., 2002. Ventilator-associated pneumonia. American Journal of 
Respiratory and Critical Care Medicine 165, 867. 
Chen, J., Chernatynskaya, A.V., Li, J.-W., Kimbrell, M.R., Cassidy, R.J., Perry, D.J., Muir, 
A.B., Atkinson, M.A., Brusko, T.M., Mathews, C.E., 2017. T cells display 
mitochondria hyperpolarization in human type 1 diabetes. Scientific Reports 
7, 10835. https://doi.org/10.1038/s41598-017-11056-9 
Chen, L., Long, X., Xu, Q., Tan, J., Wang, G., Cao, Y., Wei, J., Luo, H., Zhu, H., Huang, 
Liang, Meng, F., Huang, Lifang, Wang, N., Zhou, X., Zhao, L., Chen, X., Mao, Z., 
76 
 
Chen, C., Li, Z., Sun, Z., Zhao, J., Wang, D., Huang, G., Wang, W., Zhou, J., 2020. 
Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are 
correlated with inferior clinical outcomes in COVID-19 patients. Cellular & 
Molecular Immunology 1–3. https://doi.org/10.1038/s41423-020-0492-x 
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., 
Xia, J., Yu, T., Zhang, X., Zhang, L., 2020. Epidemiological and clinical 
characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, 
China: a descriptive study. The Lancet 395, 507–513. 
https://doi.org/10.1016/S0140-6736(20)30211-7 
Chia, S.B., Elko, E.A., Aboushousha, R., Manuel, A.M., van de Wetering, C., Druso, J.E., 
van der Velden, J., Seward, D.J., Anathy, V., Irvin, C.G., Lam, Y.-W., van der 
Vliet, A., Janssen-Heininger, Y.M.W., 2019. Dysregulation of the 
glutaredoxin/S-glutathionylation redox axis in lung diseases. American 
Journal of Physiology-Cell Physiology 318, C304–C327. 
https://doi.org/10.1152/ajpcell.00410.2019 
Cho, H.-Y., Jedlicka, A.E., Reddy, S.P.M., Kensler, T.W., Yamamoto, M., Zhang, L.-Y., 
Kleeberger, S.R., 2002. Role of NRF2 in Protection Against Hyperoxic Lung 
Injury in Mice. Am J Respir Cell Mol Biol 26, 175–182. 
https://doi.org/10.1165/ajrcmb.26.2.4501 
Choi, A.M., Alam, J., 1996. Heme oxygenase-1: function, regulation, and implication of 
a novel stress-inducible protein in oxidant-induced lung injury. Am J Respir 
Cell Mol Biol 15, 9–19. https://doi.org/10.1165/ajrcmb.15.1.8679227 
Chung, S.W., Liu, X., Macias, A.A., Baron, R.M., Perrella, M.A., 2008. Heme oxygenase-
1–derived carbon monoxide enhances the host defense response to microbial 
sepsis in mice. J. Clin. Invest. 118, 239–247. 
https://doi.org/10.1172/JCI32730 
Clerch, L.B., Massaro, D., 1993. Tolerance of rats to hyperoxia. Lung antioxidant 
enzyme gene expression. Journal of Clinical Investigation 91, 499–508. 
https://doi.org/10.1172/JCI116228 
Coperchini, F., Chiovato, L., Croce, L., Magri, F., Rotondi, M., 2020. The cytokine storm 
in COVID-19: An overview of the involvement of the chemokine/chemokine-
receptor system. Cytokine & Growth Factor Reviews 53, 25–32. 
https://doi.org/10.1016/j.cytogfr.2020.05.003 
Cotoia, A., Spadaro, S., Gambetti, G., Koulenti, D., Cinnella, G., 2020. Pathogenesis-
Targeted Preventive Strategies for Multidrug Resistant Ventilator-Associated 
Pneumonia: A Narrative Review. Microorganisms 8. 
https://doi.org/10.3390/microorganisms8060821 
Craven, D.E., Kunches, L.M., Kilinsky, V., Lichtenberg, D.A., Make, B.J., McCabe, W.R., 
1986. Risk factors for pneumonia and fatality in patients receiving 
continuous mechanical ventilation. Am Rev Respir Dis 133, 792–796. 
de Jonge, W.J., van der Zanden, E.P., The, F.O., Bijlsma, M.F., van Westerloo, D.J., 
Bennink, R.J., Berthoud, H.-R., Uematsu, S., Akira, S., van den Wijngaard, R.M., 
Boeckxstaens, G.E., 2005. Stimulation of the vagus nerve attenuates 
macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. 
Immunol. 6, 844–851. https://doi.org/10.1038/ni1229 
77 
 
Demicheli, V., Moreno, D.M., Radi, R., 2018. Human Mn-superoxide dismutase 
inactivation by peroxynitrite: a paradigm of metal-catalyzed tyrosine 
nitration in vitro and in vivo. Metallomics 10, 679–695. 
https://doi.org/10.1039/C7MT00348J 
Dennery, P.A., Spitz, D.R., Yang, G., Tatarov, A., Lee, C.S., Shegog, M.L., Poss, K.D., 
1998. Oxygen toxicity and iron accumulation in the lungs of mice lacking 
heme oxygenase-2. J. Clin. Invest. 101, 1001–1011. 
https://doi.org/10.1172/JCI448 
Dennery, P.A., Visner, G., Weng, Y. i-Hao, Nguyen, X., Lu, F., Zander, D., Yang, G., 2003. 
Resistance to hyperoxia with heme oxygenase-1 disruption: role of iron. Free 
Radic. Biol. Med. 34, 124–133. https://doi.org/10.1016/s0891-
5849(02)01295-9 
Dikalova, A.E., Itani, H.A., Nazarewicz, R.R., McMaster, W.G., Flynn, C.R., Uzhachenko, 
R., Fessel, J.P., Gamboa, J.L., Harrison, D.G., Dikalov, S.I., 2017. Sirt3 
Impairment and SOD2 Hyperacetylation in Vascular Oxidative Stress and 
Hypertension. Circ. Res. 121, 564–574. 
https://doi.org/10.1161/CIRCRESAHA.117.310933 
Dinesh, P., Rasool, M., 2017. Berberine, an isoquinoline alkaloid suppresses TXNIP 
mediated NLRP3 inflammasome activation in MSU crystal stimulated RAW 
264.7 macrophages through the upregulation of Nrf2 transcription factor and 
alleviates MSU crystal induced inflammation in rats. International 
Immunopharmacology 44, 26–37. 
https://doi.org/10.1016/j.intimp.2016.12.031 
Düssmann, H., Perez-Alvarez, S., Anilkumar, U., Papkovsky, D.B., Prehn, J.H., 2017. 
Single-cell time-lapse imaging of intracellular O 2 in response to metabolic 
inhibition and mitochondrial cytochrome- c release. Cell Death & Disease 8, 
e2853–e2853. https://doi.org/10.1038/cddis.2017.247 
Entezari, M., Javdan, M., Antoine, D.J., Morrow, D.M.P., Sitapara, R.A., Patel, V., Wang, 
M., Sharma, L., Gorasiya, S., Zur, M., 2014. Inhibition of Extracellular HMGB1 
Attenuates Hyperoxia-Induced Inflammatory Acute Lung Injury. Redox 
Biology. 
Entezari, M., Weiss, D.J., Sitapara, R., Whittaker, L., Wargo, M.J., Li, J., Wang, H., Yang, 
H., Sharma, L., Phan, B.D., 2012. Inhibition of high-mobility group box 1 
protein (HMGB1) enhances bacterial clearance and protects against 
Pseudomonas aeruginosa pneumonia in cystic fibrosis. Molecular Medicine 
18, 477. 
Fan, E., Beitler, J.R., Brochard, L., Calfee, C.S., Ferguson, N.D., Slutsky, A.S., Brodie, D., 
2020. COVID-19-associated acute respiratory distress syndrome: is a 
different approach to management warranted? The Lancet Respiratory 
Medicine 8, 816–821. https://doi.org/10.1016/S2213-2600(20)30304-0 
Farsalinos, K., Angelopoulou, A., Alexandris, N., Poulas, K., 2020a. COVID-19 and the 
nicotinic cholinergic system. Eur Respir J 56. 
https://doi.org/10.1183/13993003.01589-2020 
Farsalinos, K., Eliopoulos, E., Leonidas, D., Papadopoulos, G., Tzartos, S., Poulas, K., 
2020b. Molecular Modelling and Docking Experiments Examining the 





Faure, E., Kwong, K., Nguyen, D., 2018. Pseudomonas aeruginosa in Chronic Lung 
Infections: How to Adapt Within the Host? Front Immunol 9. 
https://doi.org/10.3389/fimmu.2018.02416 
Findlay, V.J., Townsend, D.M., Morris, T.E., Fraser, J.P., He, L., Tew, K.D., 2006. A Novel 
Role for Human Sulfiredoxin in the Reversal of Glutathionylation. Cancer Res 
66, 6800–6806. https://doi.org/10.1158/0008-5472.CAN-06-0484 
Fonseca, R.C., Bassi, G.S., Brito, C.C., Rosa, L.B., David, B.A., Araújo, A.M., Nóbrega, N., 
Diniz, A.B., Jesus, I.C.G., Barcelos, L.S., Fontes, M.A.P., Bonaventura, D., 
Kanashiro, A., Cunha, T.M., Guatimosim, S., Cardoso, V.N., Fernandes, S.O.A., 
Menezes, G.B., de Lartigue, G., Oliveira, A.G., 2019. Vagus nerve regulates the 
phagocytic and secretory activity of resident macrophages in the liver. Brain 
Behav. Immun. 81, 444–454. https://doi.org/10.1016/j.bbi.2019.06.041 
Freeman, B.A., Topolosky, M.K., Crapo, J.D., 1982. Hyperoxia increases oxygen radical 
production in rat lung homogenates. Archives of Biochemistry and 
Biophysics 216, 477–484. https://doi.org/10.1016/0003-9861(82)90236-3 
Fukai, T., Ushio-Fukai, M., 2011. Superoxide Dismutases: Role in Redox Signaling, 
Vascular Function, and Diseases. Antioxidants & Redox Signaling 15, 1583–
1606. https://doi.org/10.1089/ars.2011.3999 
Garg, B.K., Loring, R.H., 2019. GTS-21 has cell-specific anti-inflammatory effects 
independent of α7 nicotinic acetylcholine receptors. PLoS ONE 14, e0214942. 
https://doi.org/10.1371/journal.pone.0214942 
Gielis, J.F., Beckers, P.A.J., Briedé, J.J., Cos, P., Van Schil, P.E., 2017. Oxidative and 
nitrosative stress during pulmonary ischemia-reperfusion injury: from the 
lab to the OR. Annals of Translational Medicine 5, 4. 
https://doi.org/10.21037/atm.2017.03.32 
Gonzalez-Rubio, J., Navarro-Lopez, C., Lopez-Najera, E., Lopez-Najera, A., Jimenez-
Diaz, L., Navarro-Lopez, J.D., Najera, A., 2020. Cytokine Release Syndrome 
(CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm. Front. 
Immunol. 11. https://doi.org/10.3389/fimmu.2020.01359 
Gore, A., Gauthier, A.G., Lin, M., Patel, V., Thomas, D.D., Ashby, C.R., Mantell, L.L., 
2020. The nitric oxide donor, (Z)-1-[N-(2-aminoethyl)-N-(2-
ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA-NONOate/D-NO), 
increases survival by attenuating hyperoxia-compromised innate immunity 
in bacterial clearance in a mouse model of ventilator-associated pneumonia. 
Biochemical Pharmacology 113817. 
https://doi.org/10.1016/j.bcp.2020.113817 
Gore, A., Muralidhar, M., Espey, M.G., Degenhardt, K., Mantell, L.L., 2010. Hyperoxia 
sensing: From molecular mechanisms to significance in disease. Journal of 
Immunotoxicology 7, 239–254. 
https://doi.org/10.3109/1547691X.2010.492254 
Goscin, S.A., Fridovich, I., 1973. Superoxide Dismutase and the Oxygen Effect. Radiat 
Res 56, 565–569. https://doi.org/10.2307/3573726 
79 
 
Griffith, B., Pendyala, S., Hecker, L., Lee, P.J., Natarajan, V., Thannickal, V.J., 2009. NOX 
Enzymes and Pulmonary Disease. Antioxid Redox Signal 11, 2505–2516. 
https://doi.org/10.1089/ars.2009.2599 
Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., 
Hui, D.S.C., Du, B., Li, L.-J., Zeng, G., Yuen, K.-Y., Chen, R.-C., Tang, C.-L., Wang, 
T., Chen, P.-Y., Xiang, J., Li, S.-Y., Wang, J.-L., Liang, Z.-J., Peng, Y.-X., Wei, L., Liu, 
Y., Hu, Y.-H., Peng, P., Wang, J.-M., Liu, J.-Y., Chen, Z., Li, G., Zheng, Z.-J., Qiu, S.-
Q., Luo, J., Ye, C.-J., Zhu, S.-Y., Zhong, N.-S., China Medical Treatment Expert 
Group for Covid-19, 2020. Clinical Characteristics of Coronavirus Disease 
2019 in China. N. Engl. J. Med. 382, 1708–1720. 
https://doi.org/10.1056/NEJMoa2002032 
Guo, C., Sun, L., Chen, X., Zhang, D., 2013. Oxidative stress, mitochondrial damage and 
neurodegenerative diseases. Neural Regen Res 8, 2003–2014. 
https://doi.org/10.3969/j.issn.1673-5374.2013.21.009 
Hartl, D., Tirouvanziam, R., Laval, J., Greene, C.M., Habiel, D., Sharma, L., Yildirim, 
A.Ö., Dela Cruz, C.S., Hogaboam, C.M., 2018. Innate Immunity of the Lung: 
From Basic Mechanisms to Translational Medicine. JIN 10, 487–501. 
https://doi.org/10.1159/000487057 
Hartwig, J.H., Yin, H.L., 1988. The organization and regulation of the macrophage 
actin skeleton. Cell Motility 10, 117–125. 
https://doi.org/10.1002/cm.970100116 
Hauser, A.R., 2011. Pseudomonas aeruginosa: So Many Virulence Factors, So Little 
Time. Crit Care Med 39, 2193–2194. 
https://doi.org/10.1097/CCM.0b013e318221742d 
Ho, Y.S., Dey, M.S., Crapo, J.D., 1996. Antioxidant enzyme expression in rat lungs 
during hyperoxia. Am. J. Physiol. 270, L810-818. 
https://doi.org/10.1152/ajplung.1996.270.5.L810 
Hoffman, D.L., Brookes, P.S., 2009. Oxygen Sensitivity of Mitochondrial Reactive 
Oxygen Species Generation Depends on Metabolic Conditions. J Biol Chem 
284, 16236–16245. https://doi.org/10.1074/jbc.M809512200 
Hoover, D.B., 2017. Cholinergic Modulation of the Immune System Presents New 
Approaches for Treating Inflammation. Pharmacol Ther 179, 1–16. 
https://doi.org/10.1016/j.pharmthera.2017.05.002 
Horenstein, N.A., Papke, R.L., Kulkarni, A.R., Chaturbhuj, G.U., Stokes, C., Manther, K., 
Thakur, G.A., 2016. Critical molecular determinants of α7 nicotinic 
acetylcholine receptor allosteric activation: separation of direct allosteric 
activation and positive allosteric modulation. J. Biol. Chem. jbc.M115.692392. 
https://doi.org/10.1074/jbc.M115.692392 
Hu, Q., Du, M.-H., Hu, S., Chai, J., Luo, H.-M., Hu, X.-H., Zhang, L., Lin, Z.-L., Ma, L., Wang, 
H., Sheng, Z.-Y., 2014. PNU-282987 Improves the Hemodynamic Parameters 
by Alleviating Vasopermeability and Tissue Edema in Dogs Subjected to a 
Lethal Burns Shock: Journal of Burn Care & Research 35, e197–e204. 
https://doi.org/10.1097/BCR.0b013e31829afe46 
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 
Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., Xiao, Y., 
Gao, H., Guo, L., Xie, J., Wang, G., Jiang, R., Gao, Z., Jin, Q., Wang, J., Cao, B., 2020. 
80 
 
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, 
China. The Lancet 395, 497–506. https://doi.org/10.1016/S0140-
6736(20)30183-5 
Hurd, T.R., Costa, N.J., Dahm, C.C., Beer, S.M., Brown, S.E., Filipovska, A., Murphy, M.P., 
2005. Glutathionylation of mitochondrial proteins. Antioxid. Redox Signal. 7, 
999–1010. https://doi.org/10.1089/ars.2005.7.999 
Huston, J.M., Gallowitsch-Puerta, M., Ochani, M., Ochani, K., Yuan, R., Rosas-Ballina, 
M., Ashok, M., Goldstein, R.S., Chavan, S., Pavlov, V.A., Metz, C.N., Yang, H., 
Czura, C.J., Wang, H., Tracey, K.J., 2007. Transcutaneous vagus nerve 
stimulation reduces serum high mobility group box 1 levels and improves 
survival in murine sepsis *. Critical Care Medicine 35, 2762–2768. 
Huston, J.M., Rosas-Ballina, M., Xue, X., Dowling, O., Ochani, K., Ochani, M., Yeboah, 
M.M., Chatterjee, P.K., Tracey, K.J., Metz, C.N., 2009. Cholinergic Neural Signals 
to the Spleen Down-Regulate Leukocyte Trafficking via CD11b. J Immunol 
183, 552–559. https://doi.org/10.4049/jimmunol.0802684 
Immune-Based Therapy | Coronavirus Disease COVID-19 [WWW Document], n.d. . 
COVID-19 Treatment Guidelines. URL 
https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/ 
(accessed 7.14.20). 
Indo, H.P., Yen, H.-C., Nakanishi, I., Matsumoto, K.-I., Tamura, M., Nagano, Y., Matsui, 
H., Gusev, O., Cornette, R., Okuda, T., Minamiyama, Y., Ichikawa, H., Suenaga, 
S., Oki, M., Sato, T., Ozawa, T., Clair, D.K.S., Majima, H.J., 2015. A mitochondrial 
superoxide theory for oxidative stress diseases and aging. J Clin Biochem 
Nutr 56, 1–7. https://doi.org/10.3164/jcbn.14-42 
Jaffal, K., Six, S., Zerimech, F., Nseir, S., 2017. Relationship between hyperoxemia and 
ventilator associated pneumonia. Ann. Transl. Med. 453–453. 
https://doi.org/10.21037/atm.2017.10.15 
Janssen-Heininger, Y.M.W., Nolin, J.D., Hoffman, S.M., van der Velden, J.L., Tully, J.E., 
Lahue, K.G., Abdalla, S.T., Chapman, D.G., Reynaert, N.L., van der Vliet, A., 
Anathy, V., 2013. Emerging Mechanisms of Glutathione-dependent Chemistry 
in Biology and Disease. J Cell Biochem 114. 
https://doi.org/10.1002/jcb.24551 
Jin, J.-M., Bai, P., He, W., Wu, F., Liu, X.-F., Han, D.-M., Liu, S., Yang, J.-K., 2020. Gender 
Differences in Patients With COVID-19: Focus on Severity and Mortality. 
Front. Public Health 8, 152. https://doi.org/10.3389/fpubh.2020.00152 
Kallet, R.H., Branson, R.D., 2016. Should Oxygen Therapy Be Tightly Regulated to 
Minimize Hyperoxia in Critically Ill Patients? Respir Care 61, 801–817. 
https://doi.org/10.4187/respcare.04933 
Kallet, R.H., Matthay, M.A., 2013. Hyperoxic acute lung injury. Respiratory care 58, 
123–141. https://doi.org/10.4187/respcare.01963 [doi] 
Kessler, W., Diedrich, S., Menges, P., Ebker, T., Nielson, M., Partecke, L.I., Traeger, T., 
Cziupka, K., van der Linde, J., Puls, R., Busemann, A., Heidecke, C.-D., Maier, S., 
2012. The Role of the Vagus Nerve: Modulation of the Inflammatory Reaction 




Kim, Y.S., Gupta Vallur, P., Phaëton, R., Mythreye, K., Hempel, N., 2017. Insights into 
the Dichotomous Regulation of SOD2 in Cancer. Antioxidants (Basel) 6. 
https://doi.org/10.3390/antiox6040086 
Koenig, S.M., Truwit, J.D., 2006. Ventilator-associated pneumonia: diagnosis, 
treatment, and prevention. Clin. Microbiol. Rev. 19, 637–657. 
https://doi.org/10.1128/CMR.00051-05 
Kokubo, K., Soeda, S., Shinbo, T., Hirose, M., Fuku, N., Nishigaki, Y., Tanaka, M., 
Kobayashi, H., 2010. Macrophages that survive hyperoxia exposure have 
higher superoxide dismutase activities in their mitochondria. Adv. Exp. Med. 
Biol. 662, 63–69. https://doi.org/10.1007/978-1-4419-1241-1_8 
Kollef, M.H., Hamilton, C.W., Ernst, F.R., 2012. Economic impact of ventilator-
associated pneumonia in a large matched cohort. Infect Control Hosp 
Epidemiol 33, 250–256. https://doi.org/10.1086/664049 
Lee, D.W., Gardner, R., Porter, D.L., Louis, C.U., Ahmed, N., Jensen, M., Grupp, S.A., 
Mackall, C.L., 2014. Current concepts in the diagnosis and management of 
cytokine release syndrome. Blood 124, 188–195. 
https://doi.org/10.1182/blood-2014-05-552729 
Lee, P.J., Alam, J., Sylvester, S.L., Inamdar, N., Otterbein, L., Choi, A.M., 1996. 
Regulation of heme oxygenase-1 expression in vivo and in vitro in hyperoxic 
lung injury. Am J Respir Cell Mol Biol 14, 556–568. 
https://doi.org/10.1165/ajrcmb.14.6.8652184 
Leung, J.M., Yang, C.X., Sin, D.D., 2020. COVID-19 and Nicotine as a Mediator of ACE-
2. European Respiratory Journal. https://doi.org/10.1183/13993003.01261-
2020 
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., Shaman, J., 2020. Substantial 
undocumented infection facilitates the rapid dissemination of novel 
coronavirus (SARS-CoV-2). Science 368, 489–493. 
https://doi.org/10.1126/science.abb3221 
Li, X., Fang, P., Mai, J., Choi, E.T., Wang, H., Yang, X., 2013. Targeting mitochondrial 
reactive oxygen species as novel therapy for inflammatory diseases and 
cancers. Journal of Hematology & Oncology 6, 19. 
https://doi.org/10.1186/1756-8722-6-19 
Lin, M.T., Beal, M.F., 2006. Mitochondrial dysfunction and oxidative stress in 
neurodegenerative diseases. Nature 443, 787–795. 
https://doi.org/10.1038/nature05292 
Lu, B., Kwan, K., Levine, Y.A., Olofsson, P.S., Yang, H., Li, J., Joshi, S., Wang, H., 
Andersson, U., Chavan, S.S., Tracey, K.J., 2014. α7 Nicotinic Acetylcholine 
Receptor Signaling Inhibits Inflammasome Activation by Preventing 
Mitochondrial DNA Release. Mol Med 20, 350–358. 
https://doi.org/10.2119/molmed.2013.00117 
M. Fetherolf, M., Boyd, S.D., Winkler, D.D., Winge, D.R., 2017. Oxygen-dependent 
activation of Cu,Zn-superoxide dismutase-1. Metallomics 9, 1047–1059. 
https://doi.org/10.1039/C6MT00298F 
Ma Cui, Beyer Andreas M., Durand Matthew, Clough Anne V., Zhu Daling, Norwood 
Toro Laura, Terashvili Maia, Ebben Johnathan D., Hill R. Blake, Audi Said H., 
Medhora Meetha, Jacobs Elizabeth R., 2018. Hyperoxia Causes Mitochondrial 
82 
 
Fragmentation in Pulmonary Endothelial Cells by Increasing Expression of 
Pro-Fission Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology 38, 
622–635. https://doi.org/10.1161/ATVBAHA.117.310605 
Mach, W.J., Thimmesch, A.R., Pierce, J.T., Pierce, J.D., 2011. Consequences of 
Hyperoxia and the Toxicity of Oxygen in the Lung. Nursing Research and 
Practice 2011, 1–7. https://doi.org/10.1155/2011/260482 
Magnet, F.S., Storre, J.H., Windisch, W., 2017. Home oxygen therapy: evidence versus 
reality. Expert Review of Respiratory Medicine 11, 425–441. 
https://doi.org/10.1080/17476348.2017.1325323 
Majima, H.J., Oberley, T.D., Furukawa, K., Mattson, M.P., Yen, H.C., Szweda, L.I., St 
Clair, D.K., 1998. Prevention of mitochondrial injury by manganese 
superoxide dismutase reveals a primary mechanism for alkaline-induced cell 
death. J. Biol. Chem. 273, 8217–8224. 
https://doi.org/10.1074/jbc.273.14.8217 
Martin, T.R., Frevert, C.W., 2005. Innate Immunity in the Lungs. Proc Am Thorac Soc 
2, 403–411. https://doi.org/10.1513/pats.200508-090JS 
Mazloom, R., 2020. Feasibility of Therapeutic Effects of the Cholinergic Anti-
Inflammatory Pathway on COVID-19 Symptoms. J Neuroimmune Pharmacol 
15, 165–166. https://doi.org/10.1007/s11481-020-09919-6 
Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., 2020. 
COVID-19: consider cytokine storm syndromes and immunosuppression. The 
Lancet 395, 1033–1034. https://doi.org/10.1016/S0140-6736(20)30628-0 
Monick, M.M., Powers, L.S., Barrett, C.W., Hinde, S., Ashare, A., Groskreutz, D.J., 
Nyunoya, T., Coleman, M., Spitz, D.R., Hunninghake, G.W., 2008. Constitutive 
ERK MAP Kinase Activity Regulates Macrophage ATP Production and 
Mitochondrial Integrity. J Immunol 180, 7485–7496. 
Morrow, D.M.P., Entezari-Zaher, T., Romashko III, J., Azghani, A.O., Javdan, M., Ulloa, 
L., Miller, E.J., Mantell, L.L., 2007. Antioxidants preserve macrophage 
phagocytosis of Pseudomonas aeruginosa during hyperoxia. Free Radical 
Biology and Medicine 42, 1338–1349. 
O’Donovan, D.J., Fernandes, C.J., 2000. Mitochondrial glutathione and oxidative 
stress: implications for pulmonary oxygen toxicity in premature infants. Mol. 
Genet. Metab. 71, 352–358. https://doi.org/10.1006/mgme.2000.3063 
Okpala, P., Omenyi, S., Ozoegwu, G., Achebe, C., 2015. Analysis of the dynamic energy 
flow associated with phagocytosis of bacteria. Heliyon 1. 
https://doi.org/10.1016/j.heliyon.2015.e00021 
Oliveira, J., Zagalo, C., Cavaco-Silva, P., 2014. Prevention of ventilator-associated 
pneumonia. Rev Port Pneumol 20, 152–161. 
https://doi.org/10.1016/j.rppneu.2014.01.002 
O’Reilly, P.J., Hickman-Davis, J.M., Davis, I.C., Matalon, S., 2003. Hyperoxia impairs 
antibacterial function of macrophages through effects on actin. Am. J. Respir. 
Cell Mol. Biol. 28, 443–450. https://doi.org/10.1165/rcmb.2002-0153OC 
Orrenius, S., Gogvadze, V., Zhivotovsky, B., 2007. Mitochondrial oxidative stress: 




Orrenius, S., Nicotera, P., Zhivotovsky, B., 2011. Cell death mechanisms and their 
implications in toxicology. Toxicol. Sci. 119, 3–19. 
https://doi.org/10.1093/toxsci/kfq268 
Otterbein, L.E., Kolls, J.K., Mantell, L.L., Cook, J.L., Alam, J., Choi, A.M.K., 1999. 
Exogenous administration of heme oxygenase-1 by gene transfer provides 
protection against hyperoxia-induced lung injury. J. Clin. Invest. 103, 1047–
1054. https://doi.org/10.1172/JCI5342 
Ozden, O., Park, S.-H., Kim, H.-S., Jiang, H., Coleman, M.C., Spitz, D.R., Gius, D., 2011. 
Acetylation of MnSOD directs enzymatic activity responding to cellular 
nutrient status or oxidative stress. Aging (Albany NY) 3, 102–107. 
Pagano, A., Barazzone-Argiroffo, C., 2003. Alveolar Cell Death in Hyperoxia-Induced 
Lung Injury. Annals of the New York Academy of Sciences 1010, 405–416. 
https://doi.org/10.1196/annals.1299.074 
Pak, O., Sommer, N., Hoeres, T., Bakr, A., Waisbrod, S., Sydykov, A., Haag, D., 
Esfandiary, A., Kojonazarov, B., Veit, F., Fuchs, B., Weisel, F.C., Hecker, M., 
Schermuly, R.T., Grimminger, F., Ghofrani, H.A., Seeger, W., Weissmann, N., 
2013. Mitochondrial hyperpolarization in pulmonary vascular remodeling. 
Mitochondrial uncoupling protein deficiency as disease model. Am. J. Respir. 
Cell Mol. Biol. 49, 358–367. https://doi.org/10.1165/rcmb.2012-0361OC 
Papke, R.L., Chojnacka, K., Horenstein, N.A., 2014. The Minimal Pharmacophore for 
Silent Agonism of the α7 Nicotinic Acetylcholine Receptor. J Pharmacol Exp 
Ther 350, 665–680. https://doi.org/10.1124/jpet.114.215236 
Papke, R.L., Stokes, C., Damaj, M.I., Thakur, G.A., Manther, K., Treinin, M., Bagdas, D., 
Kulkarni, A.R., Horenstein, N.A., 2018. Persistent activation of α7 nicotinic 
ACh receptors associated with stable induction of different desensitized 
states. Br J Pharmacol 175, 1838–1854. https://doi.org/10.1111/bph.13851 
Parinandi, N.L., Kleinberg, M.A., Usatyuk, P.V., Cummings, R.J., Pennathur, A., 
Cardounel, A.J., Zweier, J.L., Garcia, J.G.N., Natarajan, V., 2003. Hyperoxia-
induced NAD(P)H oxidase activation and regulation by MAP kinases in 
human lung endothelial cells. Am. J. Physiol. Lung Cell Mol. Physiol. 284, L26-
38. https://doi.org/10.1152/ajplung.00123.2002 
Park, J.-B., 2003. Phagocytosis induces superoxide formation and apoptosis in 
macrophages. Experimental & Molecular Medicine 35, 325–335. 
https://doi.org/10.1038/emm.2003.44 
Patel, H., McIntire, J., Ryan, S., Dunah, A., Loring, R., 2017. Anti-inflammatory effects 
of astroglial α7 nicotinic acetylcholine receptors are mediated by inhibition 
of the NF-κB pathway and activation of the Nrf2 pathway. J 
Neuroinflammation 14. https://doi.org/10.1186/s12974-017-0967-6 
Patel, V., Dial, K., Wu, J., Gauthier, A.G., Wu, W., Lin, M., Espey, M.G., Thomas, D.D., 
Ashby, C.R., Mantell, L.L., 2020. Dietary Antioxidants Significantly Attenuate 
Hyperoxia-Induced Acute Inflammatory Lung Injury by Enhancing 
Macrophage Function via Reducing the Accumulation of Airway HMGB1. IJMS 
21, 977. https://doi.org/10.3390/ijms21030977 
Patel, V.S., Sampat, V., Espey, M.G., Sitapara, R., Wang, H., Yang, X., Ashby, C.R.J., 
Thomas, D.D., Mantell, L.L., 2016. Ascorbic Acid Attenuates Hyperoxia-
Compromised Host Defense against Pulmonary Bacterial Infection. American 
84 
 
journal of respiratory cell and molecular biology 55, 511–520. 
https://doi.org/10.1165/rcmb.2015-0310OC 
Patel, V.S., Sitapara, R.A., Gore, A., Phan, B., Sharma, L., Sampat, V., Li, J.H., Yang, H., 
Chavan, S.S., Wang, H., 2013. High Mobility Group Box–1 Mediates Hyperoxia-
Induced Impairment of Pseudomonas aeruginosa Clearance and 
Inflammatory Lung Injury in Mice. American journal of respiratory cell and 
molecular biology 48, 280–287. 
Patil, N.K., Saba, H., MacMillan-Crow, L.A., 2013. Effect of S-nitrosoglutathione on 
renal mitochondrial function: a new mechanism for reversible regulation of 
manganese superoxide dismutase activity? Free Radic. Biol. Med. 56, 54–63. 
https://doi.org/10.1016/j.freeradbiomed.2012.12.001 
Pavlov, V.A., Wang, H., Czura, C.J., Friedman, S.G., Tracey, K.J., 2003. The Cholinergic 
Anti-inflammatory Pathway: A Missing Link in Neuroimmunomodulation. 
Mol Med 9, 125–134. 
Pendyala, S., Gorshkova, I.A., Usatyuk, P.V., He, D., Pennathur, A., Lambeth, J.D., 
Thannickal, V.J., Natarajan, V., 2009. Role of Nox4 and Nox2 in hyperoxia-
induced reactive oxygen species generation and migration of human lung 
endothelial cells. Antioxid. Redox Signal. 11, 747–764. 
https://doi.org/10.1089/ars.2008.2203 
Perl, A., Gergely, P., Nagy, G., Koncz, A., Banki, K., 2004. Mitochondrial 
hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. 
Trends Immunol 25, 360–367. https://doi.org/10.1016/j.it.2004.05.001 
Petrache, I., Choi, M.E., Otterbein, L.E., Chin, B.Y., Mantell, L.L., Horowitz, S., Choi, 
A.M.K., 1999. Mitogen-activated protein kinase pathway mediates  hyperoxia-
induced apoptosis in cultured macrophage cells. American Journal of 
Physiology-Lung Cellular and Molecular Physiology 277, L589–L595. 
https://doi.org/10.1152/ajplung.1999.277.3.L589 
Pham, T., Brochard, L.J., Slutsky, A.S., 2017. Mechanical Ventilation: State of the Art. 
Mayo Clin. Proc. 92, 1382–1400. 
https://doi.org/10.1016/j.mayocp.2017.05.004 
Polosa, R., Caci, G., 2020. COVID-19: counter-intuitive data on smoking prevalence 
and therapeutic implications for nicotine. Intern Emerg Med 1–4. 
https://doi.org/10.1007/s11739-020-02361-9 
Pranikoff, T., Hirschl, R.B., Steimle, C.N., Anderson, H.L., Bartlett, R.H., 1997. Mortality 
is directly related to the duration of mechanical ventilation before the 
initiation of extracorporeal life support for severe respiratory failure: Critical 
Care Medicine 25, 28–32. https://doi.org/10.1097/00003246-199701000-
00008 
Rael, L.T., Bar-Or, R., Salottolo, K., Mains, C.W., Slone, D.S., Offner, P.J., Bar-Or, D., 
2009. Injury severity and serum amyloid A correlate with plasma oxidation-
reduction potential in multi-trauma patients: a retrospective analysis. Scand J 
Trauma Resusc Emerg Med 17, 57. https://doi.org/10.1186/1757-7241-17-
57 
Rafikov, R., Nair, V., Sinari, S., Babu, H., Sullivan, J.C., Yuan, J.X.-J., Desai, A.A., Rafikova, 
O., 2019. Gender Difference in Damage-Mediated Signaling Contributes to 
85 
 
Pulmonary Arterial Hypertension. Antioxidants & Redox Signaling 31, 917–
932. https://doi.org/10.1089/ars.2018.7664 
Ratner, V., Starkov, A., Matsiukevich, D., Polin, R.A., Ten, V.S., 2009. Mitochondrial 
Dysfunction Contributes to Alveolar Developmental Arrest in Hyperoxia-
Exposed Mice. Am J Respir Cell Mol Biol 40, 511–518. 
https://doi.org/10.1165/rcmb.2008-0341RC 
Reddy, N.M., Kleeberger, S.R., Kensler, T.W., Yamamoto, M., Hassoun, P.M., Reddy, 
S.P., 2009. DISRUPTION OF NRF2 IMPAIRS THE RESOLUTION OF 
HYPEROXIA-INDUCED ACUTE LUNG INJURY AND INFLAMMATION IN MICE. J 
Immunol 182, 7264. https://doi.org/10.4049/jimmunol.0804248 
Rello, J., 2005. Bench-to-bedside review: Therapeutic options and issues in the 
management of ventilator-associated bacterial pneumonia. Crit Care 9, 259–
265. https://doi.org/10.1186/cc3014 
Rello, J., Ollendorf, D.A., Oster, G., Vera-Llonch, M., Bellm, L., Redman, R., Kollef, M.H., 
2002. Epidemiology and outcomes of ventilator-associated pneumonia in a 
large US database. CHEST Journal 122, 2115–2121. 
Renda, T., Corrado, A., Iskandar, G., Pelaia, G., Abdalla, K., Navalesi, P., 2018. High-
flow nasal oxygen therapy in intensive care and anaesthesia. British Journal 
of Anaesthesia 120, 18–27. https://doi.org/10.1016/j.bja.2017.11.010 
Resseguie, E.A., Staversky, R.J., Brookes, P.S., O’Reilly, M.A., 2015. Hyperoxia 
activates ATM independent from mitochondrial ROS and dysfunction. Redox 
Biology 5, 176–185. https://doi.org/10.1016/j.redox.2015.04.012 
Richards, M.J., Edwards, J.R., Culver, D.H., Gaynes, R.P., 1999. Nosocomial infections 
in medical intensive care units in the United States. National Nosocomial 
Infections Surveillance System. Crit. Care Med. 27, 887–892. 
https://doi.org/10.1097/00003246-199905000-00020 
Rothan, H.A., Byrareddy, S.N., 2020. The epidemiology and pathogenesis of 
coronavirus disease (COVID-19) outbreak. J Autoimmun 109, 102433. 
https://doi.org/10.1016/j.jaut.2020.102433 
Rudyk, O., Eaton, P., 2014. Biochemical methods for monitoring protein thiol redox 
states in biological systems. Redox Biol 2, 803–813. 
https://doi.org/10.1016/j.redox.2014.06.005 
Ryter, S.W., Choi, A.M.K., 2016. Targeting Heme Oxygenase-1/Carbon Monoxide for 
Therapeutic Modulation of Inflammation. Transl Res 167, 7–34. 
https://doi.org/10.1016/j.trsl.2015.06.011 
Ryter, S.W., Choi, A.M.K., 2013. Carbon monoxide in exhaled breath testing and 
therapeutics. J. Breath Res. 7, 017111. https://doi.org/10.1088/1752-
7155/7/1/017111 
Sadikot, R.T., Blackwell, T.S., Christman, J.W., Prince, A.S., 2005. Pathogen–Host 
Interactions in Pseudomonas aeruginosa Pneumonia. Am J Respir Crit Care 
Med 171, 1209–1223. https://doi.org/10.1164/rccm.200408-1044SO 
Scott, D.A., Martin, M., 2006. Exploitation of the nicotinic anti-inflammatory pathway 
for the treatment of epithelial inflammatory diseases. World J Gastroenterol 
12, 7451–7459. https://doi.org/10.3748/wjg.v12.i46.7451 
86 
 
Simons, D., Brown, J., Shahab, L., Perski, O., 2020. Smoking and COVID-19: Rapid 
evidence review for the Royal College of Physicians, London (UK). Qeios. 
https://doi.org/10.32388/VGJCUN 
Sinha, P., Matthay, M.A., Calfee, C.S., 2020. Is a “Cytokine Storm” Relevant to COVID-
19? JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2020.3313 
Sitapara, R.A., Antoine, D.J., Sharma, L., Patel, V.S., Ashby Jr, C.R., Gorasiya, S., Yang, H., 
Zur, M., Mantell, L.L., 2014. The alpha7 nicotinic acetylcholine receptor 
agonist GTS-21 improves bacterial clearance in mice by restoring hyperoxia-
compromised macrophage function. Molecular medicine (Cambridge, Mass.) 
20, 238–247. https://doi.org/10.2119/molmed.2013.00086 [doi] 
Sitapara, R.A., Gauthier, A.G., Valdés-Ferrer, S.I., Lin, M., Patel, V., Wang, M., Martino, 
A.T., Perron, J.C., Ashby, C.R., Tracey, K.J., Pavlov, V.A., Mantell, L.L., 2020. The 
α7 nicotinic acetylcholine receptor agonist, GTS-21, attenuates hyperoxia-
induced acute inflammatory lung injury by alleviating the accumulation of 
HMGB1 in the airways and the circulation. Mol. Med. 26, 63. 
https://doi.org/10.1186/s10020-020-00177-z 
Six, S., Jaffal, K., Ledoux, G., Jaillette, E., Wallet, F., Nseir, S., 2016. Hyperoxemia as a 
risk factor for ventilator-associated pneumonia. Crit Care 20, 195. 
https://doi.org/10.1186/s13054-016-1368-4 
Skok, M.V., 2009. Editorial: To channel or not to channel? Functioning of nicotinic 
acetylcholine receptors in leukocytes. J. Leukoc. Biol. 86, 1–3. 
https://doi.org/10.1189/JLB.0209106 
Skulachev, V.P., 1999. Mitochondrial physiology and pathology; concepts of 
programmed death of organelles, cells and organisms. Mol. Aspects Med. 20, 
139–184. https://doi.org/10.1016/s0098-2997(99)00008-4 
Slebos, D.-J., Ryter, S.W., Choi, A.M., 2003. Heme oxygenase-1 and carbon monoxide 
in pulmonary medicine. Respir Res 4, 7. https://doi.org/10.1186/1465-
9921-4-7 
Smith, J.L., 1899. The pathological effects due to increase of oxygen tension in the air 
breathed. The Journal of Physiology 24, 19–35. 
https://doi.org/10.1113/jphysiol.1899.sp000746 
Soares, M.P., Hamza, I., 2016. Macrophages and iron metabolism. Immunity 44, 492–
504. https://doi.org/10.1016/j.immuni.2016.02.016 
Spalding, M.C., Cripps, M.W., Minshall, C.T., 2017. Ventilator-Associated Pneumonia. 
Crit Care Clin 33, 277–292. https://doi.org/10.1016/j.ccc.2016.12.009 
Staats, P., Giannakopoulos, G., Blake, J., Liebler, E., Levy, R.M., 2020. The Use of Non-
invasive Vagus Nerve Stimulation to Treat Respiratory Symptoms Associated 
With COVID-19: A Theoretical Hypothesis and Early Clinical Experience. 
Neuromodulation. https://doi.org/10.1111/ner.13172 
Starkov, A.A., 2008. The Role of Mitochondria in Reactive Oxygen Species 
Metabolism and Signaling. Ann N Y Acad Sci 1147, 37–52. 
https://doi.org/10.1196/annals.1427.015 
Suliman, H.B., Keenan, J.E., Piantadosi, C.A., 2017. Mitochondrial quality-control 




Svitkina, T., 2018. The Actin Cytoskeleton and Actin-Based Motility. Cold Spring 
Harb Perspect Biol 10, a018267. 
https://doi.org/10.1101/cshperspect.a018267 
Tan, S.Y.S., Krasnow, M.A., 2016. Developmental origin of lung macrophage diversity. 
Development 143, 1318–1327. https://doi.org/10.1242/dev.129122 
Thakur, G.A., Kulkarni, A.R., Deschamps, J.R., Papke, R.L., 2013. Expeditious 
Synthesis, Enantiomeric Resolution and Enantiomer Functional 
Characterization of (4-(4-bromophenyl)-3a, 4, 5, 9b-tetrahydro-3H-
cyclopenta[c]quinoline-8-sulfonamide (4BP-TQS): an Allosteric agonist-
Positive Allosteric Modulator of α7 Nicotinic Acetylcholine Receptors. J Med 
Chem 56, 8943–8947. https://doi.org/10.1021/jm401267t 
Tindle, H.A., Newhouse, P.A., Freiberg, M.S., 2020. Beyond Smoking Cessation: 
Investigating Medicinal Nicotine to Prevent and Treat COVID-19. Nicotine & 
Tobacco Research ntaa077. https://doi.org/10.1093/ntr/ntaa077 
To, K.K.-W., Tsang, O.T.-Y., Leung, W.-S., Tam, A.R., Wu, T.-C., Lung, D.C., Yip, C.C.-Y., 
Cai, J.-P., Chan, J.M.-C., Chik, T.S.-H., Lau, D.P.-L., Choi, C.Y.-C., Chen, L.-L., Chan, 
W.-M., Chan, K.-H., Ip, J.D., Ng, A.C.-K., Poon, R.W.-S., Luo, C.-T., Cheng, V.C.-C., 
Chan, J.F.-W., Hung, I.F.-N., Chen, Z., Chen, H., Yuen, K.-Y., 2020. Temporal 
profiles of viral load in posterior oropharyngeal saliva samples and serum 
antibody responses during infection by SARS-CoV-2: an observational cohort 
study. The Lancet Infectious Diseases 20, 565–574. 
https://doi.org/10.1016/S1473-3099(20)30196-1 
Tracey, K.J., 2002. The inflammatory reflex. Nature 420, 853–859. 
Tsoyi, K., Jang, H.J., Kim, J.W., Chang, H.K., Lee, Y.S., Pae, H.-O., Kim, H.J., Seo, H.G., Lee, 
J.H., Chung, H.-T., Chang, K.C., 2011. Stimulation of Alpha7 Nicotinic 
Acetylcholine Receptor by Nicotine Attenuates Inflammatory Response in 
Macrophages and Improves Survival in Experimental Model of Sepsis 
Through Heme Oxygenase-1 Induction. Antioxidants & Redox Signaling 14, 
2057–2070. https://doi.org/10.1089/ars.2010.3555 
Ulloa, L., 2005. The vagus nerve and the nicotinic anti-inflammatory pathway. 
Nature Reviews Drug Discovery 4, 673–684. 
van der Vliet, A., Janssen-Heininger, Y.M.W., Anathy, V., 2018. Oxidative stress in 
chronic lung disease: From mitochondrial dysfunction to dysregulated redox 
signaling. Mol. Aspects Med. 63, 59–69. 
https://doi.org/10.1016/j.mam.2018.08.001 
Vijayan, V., Wagener, F.A.D.T.G., Immenschuh, S., 2018. The macrophage heme-heme 
oxygenase-1 system and its role in inflammation. Biochemical Pharmacology, 
Diamond Jubilee Special Issue: Celebrating 60 Years of Excellence 153, 159–
167. https://doi.org/10.1016/j.bcp.2018.02.010 
Villiger, Y., Szanto, I., Jaconi, S., Blanchet, C., Buisson, B., Krause, K.-H., Bertrand, D., 
Romand, J.-A., 2002. Expression of an alpha7 duplicate nicotinic acetylcholine 
receptor-related protein in human leukocytes. J. Neuroimmunol. 126, 86–98. 
https://doi.org/10.1016/s0165-5728(02)00057-7 
Walsh, B.K., Smallwood, C.D., 2017. Pediatric Oxygen Therapy: A Review and Update. 
Respir Care 62, 645–661. https://doi.org/10.4187/respcare.05245 
88 
 
Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, 
Y., Zhao, Y., Li, Y., Wang, X., Peng, Z., 2020. Clinical Characteristics of 138 
Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in 
Wuhan, China. JAMA 323, 1061–1069. 
https://doi.org/10.1001/jama.2020.1585 
Wang, D.-W., Yin, Y.-M., Yao, Y.-M., 2016. Vagal Modulation of the Inflammatory 
Response in Sepsis. Int. Rev. Immunol. 35, 415–433. 
https://doi.org/10.3109/08830185.2015.1127369 
Wang, H., Liao, H., Ochani, M., Justiniani, M., Lin, X., Yang, L., Al-Abed, Y., Wang, H., 
Metz, C., Miller, E.J., 2004. Cholinergic agonists inhibit HMGB1 release and 
improve survival in experimental sepsis. Nature medicine 10, 1216–1221. 
Wang, H., Yu, M., Ochani, M., Amella, C.A., Tanovic, M., Susarla, S., Li, J.H., Wang, H., 
Yang, H., Ulloa, L., Al-Abed, Y., Czura, C.J., Tracey, K.J., 2003. Nicotinic 
acetylcholine receptor alpha7 subunit is an essential regulator of 
inflammation. Nature 421, 384–388. https://doi.org/10.1038/nature01339 
Wang, J., Li, R., Peng, Z., Zhou, W., Hu, B., Rao, X., Yang, X., Li, J., 2019. GTS-21 Reduces 
Inflammation in Acute Lung Injury by Regulating M1 Polarization and 
Function of Alveolar Macrophages: SHOCK 51, 389–400. 
https://doi.org/10.1097/SHK.0000000000001144 
Wang, M., Gauthier, A., Daley, L., Dial, K., Wu, J., Woo, J., Lin, M., Ashby, C.R., Mantell, 
L., 2019. Nuclear Damage Associated Molecular Pattern (DAMP) Molecule 
HMGB1 in the Pathogenesis of Lung Diseases. Antioxid. Redox Signal. 
https://doi.org/10.1089/ars.2019.7818 
Wang, M., Gorasiya, S., Antoine, D.J., Sitapara, R.A., Wu, W., Sharma, L., Yang, H., 
Ashby, C.R., Vasudevan, D., Zur, M., Thomas, D.D., Mantell, L.L., 2015. The 
Compromise of Macrophage Functions by Hyperoxia Is Attenuated by 
Ethacrynic Acid via Inhibition of NF-κB–Mediated Release of High-Mobility 
Group Box-1. Am J Respir Cell Mol Biol 52, 171–182. 
https://doi.org/10.1165/rcmb.2013-0544OC 
Wang, X., Wang, Y., Kim, H.P., Nakahira, K., Ryter, S.W., Choi, A.M.K., 2007. Carbon 
Monoxide Protects against Hyperoxia-induced Endothelial Cell Apoptosis by 
Inhibiting Reactive Oxygen Species Formation. J. Biol. Chem. 282, 1718–1726. 
https://doi.org/10.1074/jbc.M607610200 
Wang, Y., Branicky, R., Noë, A., Hekimi, S., 2018. Superoxide dismutases: Dual roles in 
controlling ROS damage and regulating ROS signaling. J. Cell Biol. 217, 1915–
1928. https://doi.org/10.1083/jcb.201708007 
Ward, N.S., Waxman, A.B., Homer, R.J., Mantell, L.L., Einarsson, O., Du, Y., Elias, J.A., 
2000. Interleukin-6-induced protection in hyperoxic acute lung injury. Am. J. 
Respir. Cell Mol. Biol. 22, 535–542. 
https://doi.org/10.1165/ajrcmb.22.5.3808 
Wilson, C., Terman, J.R., González‐Billault, C., Ahmed, G., 2016. Actin filaments—A 
target for redox regulation. Cytoskeleton 73, 577–595. 
https://doi.org/10.1002/cm.21315 
Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, Xing, Xu, S., Huang, H., Zhang, L., Zhou, Xia, Du, C., 
Zhang, Y., Song, J., Wang, S., Chao, Y., Yang, Z., Xu, J., Zhou, Xin, Chen, D., Xiong, 
89 
 
W., Xu, L., Zhou, F., Jiang, J., Bai, C., Zheng, J., Song, Y., 2020. Risk Factors 
Associated With Acute Respiratory Distress Syndrome and Death in Patients 
With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern 
Med 180, 934–943. https://doi.org/10.1001/jamainternmed.2020.0994 
Wu, H., Li, L., Su, X., 2014. Vagus Nerve through 7 nAChR Modulates Lung Infection 
and Inflammation: Models, Cells, and Signals. BioMed research international 
2014. 
Yamakura, F., Kawasaki, H., 2010. Post-translational modifications of superoxide 
dismutase. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, 
Carbonic Anhydrase and Superoxide Dismutase 1804, 318–325. 
https://doi.org/10.1016/j.bbapap.2009.10.010 
Yang, H., Liu, H., Zeng, Q., Imperato, G.H., Addorisio, M.E., Li, J., He, M., Cheng, K.F., Al-
Abed, Y., Harris, H.E., Chavan, S.S., Andersson, U., Tracey, K.J., 2019. Inhibition 
of HMGB1/RAGE-mediated endocytosis by HMGB1 antagonist box A, anti-
HMGB1 antibodies, and cholinergic agonists suppresses inflammation. Mol 
Med 25, 13. https://doi.org/10.1186/s10020-019-0081-6 
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., Yu, T., 
Wang, Y., Pan, S., Zou, X., Yuan, S., Shang, Y., 2020. Clinical course and 
outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, 
China: a single-centered, retrospective, observational study. The Lancet 
Respiratory Medicine 8, 475–481. https://doi.org/10.1016/S2213-
2600(20)30079-5 
Zemskova, M., Kurdyukov, S., James, J., McClain, N., Rafikov, R., Rafikova, O., 2020. 
Sex-specific stress response and HMGB1 release in pulmonary endothelial 
cells. PLoS ONE 15, e0231267. 
https://doi.org/10.1371/journal.pone.0231267 
Zhang, Q., Lai, Y., Deng, J., Wang, Menglong, Wang, Z., Wang, Meng, Zhang, Y., Yang, X., 
Zhou, X., Jiang, H., 2019. Vagus Nerve Stimulation Attenuates Hepatic 
Ischemia/Reperfusion Injury via the Nrf2/HO-1 Pathway. Oxidative Medicine 
and Cellular Longevity 2019, 1–10. https://doi.org/10.1155/2019/9549506 
Zhang, X., Shan, P., Sasidhar, M., Chupp, G.L., Flavell, R.A., Choi, A.M.K., Lee, P.J., 2003. 
Reactive oxygen species and extracellular signal-regulated kinase 1/2 
mitogen-activated protein kinase mediate hyperoxia-induced cell death in 
lung epithelium. American journal of respiratory cell and molecular biology 
28, 305–315. https://doi.org/10.1165/rcmb.2002-0156OC 
Zhou, W., Yuan, X., Zhang, L., Su, B., Tian, D., Li, Y., Zhao, J., Wang, Y., Peng, S., 2017. 
Overexpression of HO-1 assisted PM2.5-induced apoptosis failure and 
autophagy-related cell necrosis. Ecotoxicology and Environmental Safety 
145, 605–614. https://doi.org/10.1016/j.ecoenv.2017.07.047 
Zimlichman, E., Henderson, D., Tamir, O., Franz, C., Song, P., Yamin, C.K., Keohane, C., 
Denham, C.R., Bates, D.W., 2013. Health Care–Associated Infections: A Meta-
analysis of Costs and Financial Impact on the US Health Care System. JAMA 
Intern Med 173, 2039–2046. 
https://doi.org/10.1001/jamainternmed.2013.9763 
Zorova, L.D., Popkov, V.A., Plotnikov, E.Y., Silachev, D.N., Pevzner, I.B., Jankauskas, 
S.S., Babenko, V.A., Zorov, S.D., Balakireva, A.V., Juhaszova, M., Sollott, S.J., 
90 
 








Name      Alex Gauthier 
 
Baccalaureate Degree   Bachelor of Science, Hofstra University 
 
      Hempstead, NY, Biochemistry 
Date Graduated    May 2015 
  
 
